CSI Textbook of Cardiology: The Indian Perspective Pradip K Deb
INDEX
Page numbers followed by b refer to box, f refer to figure, fc refer to flow chart, and t refer to table.
A
Abdominojugular reflux 29
Abluminus 493, 499, 504
SES 491
ACCORD See Action to control cardiovascular risk in diabetes
Acenocoumarol 798
advantages of 798t
limitation of 798t
Acid peptic disease 951
Acid-fast bacilli, actual visualization of 1003
Acquired immunodeficiency syndrome 910f
ACS See Acute coronary syndrome
Actinobacillus 163
Action to control cardiovascular risk in diabetes 690, 691
Activated partial thromboplastin time 72, 402, 803, 807
Active disease, treatment of 614
Acupuncture 938
Acute coronary events score, global registry of 398
Adams-Oliver syndrome 20
Adenoma 920
single 681
Adenovirus 233
Adipocytes 785
heterogeneous mix of 784
hypertrophy 784
Adipokines 372
Adipose tissue 784
propagates 785
Adrenal computed tomography scan 681
Adrenal hyperplasia, primary 679, 681
Adrenal vein sampling 681, 682fc
Adrenalectomy 681
Advanced diastolic dysfunction 275f
Adverse cardiac events, major 448, 475, 534, 535
Adverse cardiovascular events, major 497, 506
Aerobic exercise, low-intensity 251
Age and sex distribution 616t
Aggressive diuresis 11
Ain Shams scoring 106
Air pollution 983
Ajmaline 712
Alagille syndrome 20
Alanine aminotransferase 28, 797
Alcohol 359
consumption 964
intake, moderation of 449
septal ablation 248, 252, 253, 259
use 968
Aldehydes 976
Aldosterone antagonist 242
Aldosterone producing adenoma 679
surgical treatment of 681
Aldosteronism
primary 679, 680
pathophysiology 679
screening for primary 680
Alkaline phosphatase 28, 797
Allergies 131, 951
Alogliptin 994
Altruism 949
Aluminum phosphate poisoning 68
Alveolar hypoventilation disorders 188
Ambient air pollution 360
Ambrisentan 195
American College of Cardiology 76t, 99, 99t, 110t, 191, 192f, 377, 399, 447, 456, 514, 533, 577579, 779, 787, 833, 994
American College of Obstetricians and Gynaecologists Guidelines 835
American College of Rheumatology 609, 626t
American Diabetes Association 772
guidelines 693
American Heart Association 99, 107, 191, 192f, 377, 399, 456, 479, 514, 533, 577579, 779, 782, 787, 894, 974
classification 99t, 813t
guidelines 76t, 110t
American Society of Echocardiography 866, 871, 882
Amiodarone 712, 730f, 753, 802, 820
Amlodipine 656f
Amplatzer duct occlude 344f
Amplatzer vascular plug 344f
Amurosisfugax 18
Amyloidosis 233, 241, 278, 286, 740
Anacrotic notch 32, 35
Anacrotic pulse 35
Anacrotic shoulder 32
Analgesics 10
Ancillary diagnostic tests 678
Anderson Fabry disease 249
Andexanet alfa 804, 824
Anemia 6, 8, 211, 224
mild 623
Aneurysm 557
formation 325
Angina 4t, 251
pectoris 9
Angiofibroma 24
Angiogram 338f, 563f, 564f
Angiographic lesions 556
Angiographic profile 468
Angiography 281f, 922
Angioplasty 534, 667
procedures 489
Angiosarcoma 904, 932
arising 930f
Angiotensin converting enzyme inhibitors 157, 206, 222, 235, 242, 449, 653, 846
Angiotensin receptor blockers 212, 242, 449, 847
generations of 654f
Angiotensin receptor neprilysin inhibitors 74, 206
Anitschkow cells 131
Annuloaortic ectasia 610
Anomalous pulmonary venous connection, partial 20
Anorexigen 172
Antacids 820
Ant-arrhythmic drugs 753
Anthracycline 229
agents 233
Anti-anginal therapy 451
Anti-aorta antibodies 611, 622
Antiarrhythmic agents 712
Antiarrhythmic drugs 13, 242, 268, 717, 751, 908
Antiarrhythmic therapy 726
Antibody-mediated rejection 604
Anti-cellular antibodies 611
Anticoagulant
monitoring 803t
assay 803
selection of 805
therapy 438f
Anticoagulation 419, 430
role of 181
Antidepressants 10
Antidiabetic agents 994
Antidotes 803
Antihypertensive drugs 14
Antihypertensive medications 668f
Anti-ischemic therapy 451
Antineoplastic agents 233
Antinuclear antibody 82
Antioxidant 963
Antiphospholipid antibody syndrome 389
Antiplatelet 400, 808, 810
agents 751
drugs, role of 751
single 752
therapy 450
dual 438f, 450
Antiproliferative drug 492
Anti-proteinuric effect 656f
Antipsychotic drugs 970
Antiretroviral therapy, highly active 238
Antithrombotic 402, 751
therapy 809f, 815
guidelines for 796
Antitubercular drugs like isoniazid, use of 819
Antitubercular therapy 263
Antitumor necrosis 629
factor agents 295
Antivascular endothelial growth 237
Anxiety 10, 426, 951
Aorta 101, 103, 283, 557, 915
abdominal 619f
ascending 144
balloon angioplasty of 615
bifurcation, abdominal 36
coarctation of 20, 57, 66, 313, 326, 337, 338t, 549, 676
lesion, abdominal 610
narrowing of 555f
small 84f
Aortic aneurysm, abdominal 551, 552f, 553f, 560
Aortic antigen, treatment of 611
Aortic arch 555f
aneurysm 38
atheromas 548
imaging of 548
involvement of 618f
syndrome 621
types of 548, 548f
Aortic closure, early 46
Aortic coarctation 550f
Aortic diseases 549
Aortic dissection 36, 552
acute 554f
Aortic level 915f
Aortic plaque 797
Aortic prosthetic valve endocarditis 166
Aortic pulse wave velocity 774
Aortic regurgitant murmur 127
Aortic regurgitation 34, 10, 35f, 39, 46, 50, 56, 60, 131, 131, 154, 530, 610, 833, 866
acute 56t
chronic 56t
isolated 143
management of chronic 144
peripheral signs of 34t
Aortic root, dilatation of 54
Aortic stenosis 20, 46, 54t, 50, 53, 54, 60, 128, 154, 258, 313, 337, 530, 832, 866, 876
isolated 140, isolated 154f
low-gradient 158
severe 34, 572
supraventricular 20
Aortic valve 155, 854f, 874, 906f
carditis of 125
dilatation 335, 336
disease 573, 835
chronic 125
in aortic position, bileaflet 798
pathophysiology 155
prosthesis 163
regurgitation, signs of 67
repair 574
replacement 592, 740, 866
indications of 141
surgical 529
risk factors 155
Aortic valvular stenosis, causes of 140
Aortitis syndrome 621
Aortoarteritis 15, 616t, 618f, 619f, 673
early stage 15
late stage 15
management of 614
nonspecific 607, 609, 612, 617t, 621
classification 624
clinical features 623
epidemiology 621
etiopathogenesis 622
medical management 629
natural history 631
pathology 621
prognosis 631
treatment 629
ultrasound 629
progressive 678
tests for evaluation of 82b
Aortogram 344f
Aortography 555f
Aortoiliac interventions 556
Aortoiliac lesions 559
Aortoiliac occlusive disease 556
Aortopulmonary collateral 183
arteries, major 66
Aortopulmonary window 34, 177, 178
APA See Aldosterone-producing adenoma
Apical impulse, mechanism of 40f
Apixaban 802, 804, 805, 819, 821
Apolipoprotein 381, 687b
elevation of 785b
Apoptosis antigen 843
AR See Aortic regurgitation
ARAS See Atherosclerotic renal artery stenosis
Arch
anatomy 549
vessels 557
angioplasty of 615
Arm blood pressures 678f
Arm span 19
Arrhythmia 8, 32, 32t, 240, 709, 717, 733, 766, 795, 836, 907, 921
cause of 721
effect of 44
induction 722
supraventricular 247, 430, 713, 722
ventricular 247, 713
Arrhythmogenic right ventricular dysfunction 263, 266
Arterial blood gas 82
Arterial deoxygenation 8
Arterial hypertension 224
Arterial occlusion
acute 561
chronic 561
Arterial oxygen saturation 426
Arterial pulse 32
Arterial revascularization 587
therapies study 474
Arterial thrombosis 846
Arteriogram abnormality 610
Artery
calcification calculator 703
left anterior 413
descending 73
posterior descending 73
Arthralgia 622, 623
Arthritis 131, 951
treatment of 132
AS See Aortic stenosis
Aschoff bodies 125, 131
ASCVD See Atherosclerotic cardiovascular disease
Asepsis 840
Asian Indian dyslipidemia 388
Asian Indian paradox 388
Aspartate aminotransferase 28
Aspirin 128, 295, 400, 406, 408, 431, 433, 450, 986
higher doses 422
low-dose 450
Asthma 951
Astronomer 157
Asymmetrical septal hypertrophy 854f
Asymptomatic aortic stenosis, severe 861f
Atenolol 658f
unlike 658f
Atherectomy devices 561
Atherogenic dyslipidemia 369, 691, 696
Atheromatous aortic arch 548
Atherosclerosis 668f, 670, 692
marker for 785
multi ethnic study of 972, 973
premature 878
Atherosclerotic
cardiovascular disease 693, 695, 697, 702
left renal artery 668f
ostial stenosis of renal artery 555
plaque 538
renal artery stenosis 665, 669
management of 666
right renal artery 669f
vascular diseases 945
Athlete's heart 258, 861
Atorvastatin 403, 427, 706, 707, 820
study 779
Atrial appendage, left 101, 104, 753, 808
Atrial based pacemaker 754
Atrial dimensions, left 868t
Atrial enlargement, left 101, 103
Atrial fibrillation 33, 138, 208, 221, 430, 539, 572, 722, 729, 749, 750, 750t, 795, 796, 796f, 798, 800t, 801, 802f, 807, 807f, 808, 809f, 810, 846
comorbidities in 749
incidence and prevalence 749
left atrial ablation for 725f
management of 255, 751, 753fc
Atrial function, left 861
Atrial kick 141
Atrial myxoma 918
large left 914f, 928f
obstructing mitral valve, left 927f
right 915, 916, 917f, 919, 919t, 931
Atrial premature contraction 32
Atrial pressure 193
right 192
Atrial septal defect 20, 25, 31, 32, 38, 39, 50, 60, 177, 178, 311, 313, 323, 324, 340, 928, 928f
Atrial septostomy 333
Atrial septum 103, 929f
Atrial stretch 430
Atrial tachycardia 724, 725
multifocal 33
Atrial thrombus, left 103, 112
Atrial volume index, left 221, 868
Atrioventicular junction, modification of 723
Atrioventricula junction 930f
Atrioventricular block 32, 530, 739, 741, 742f, 745
acquired 715
classification 740
clinical presentation 740
complete 728, 743f
etiologies of 740
paroxysmal 743
second-degree 740
third degree 741, 745
Atrioventricular nodal re-entrant tachycardia 11, 63, 724, 732
Atrioventricular node 753
Atrioventricular septal defect 20, 177, 313, 327
Atrioventricular valve 20
Atrium
left 103, 104, 282, 286, 855, 869, 874, 878, 879, 908, 929, 930
myxoma, angiographic profiling of left 923f
right 282, 286, 879, 919, 929, 930
Atropine 743
Auenbrugger's sign 38, 43
Auscultation 43
Auscultatory signs
abnormal 58f
normal 58f
Austin-Flint murmur 56, 56t
Australasian Maternity Outcomes Surveillance System 834
Autism spectrum disorder 68
Autograft valves 594
Autoimmune mechanism 611
Autologous stem cell implantation 561
Autologous valves 594
Autosomal dominant inheritance 242
AVR See Aortic valve replacement
Awake cardiac surgery 585
Azathioprine 614
Azilsartan 653655
influences function 654f
mechanisms of action of 654f
reduces nocturnal hypertension 655f
Azithromycin 125, 128, 131
Azygos veins 12
B
B mode ultrasonography 816
Bacterial endocarditis 740
Balloon angioplasty 671f, 672f, 673
plain 561, 673
Balloon aortic valvuloplasty 142
indications of 142
Balloon atrial septostomy 196, 333
complications 333
success of procedure 333
Balloon catheter
selection of 518
system 518
Balloon dilatation 550f
Balloon mitral valvotomy 136
indications for 136
Balloon mitral valvuloplasty 514, 520, 753, 833
complications of 523
contraindications 515
development of 514
immediate results of 524
long-term results 524
patient preparation 516
periprocedural care 515
techniques 516
Balloon valve dilatations 334
Bamberger's sign 43
Bare metal
balloon-expandable stent 561
stents 489, 494, 497, 498, 554
development of 490
Barth's syndrome 233, 242
Basal cell nevus syndrome 907
Basal septal thinning 267f
Basic life support 735
Becker's muscular dystrophy 233, 242
Becker's sign 67
Behavior modification 974
Behavior therapy 787
Benidipine 655, 656f, 657, 657f
blocks 656f
Benzathine penicillin 131
Beraprost 196
Beriberi 232
Bernheim effect 30
Bernoulli effect 35f
Beta-blockers 107, 182, 222, 433, 452, 740, 986
Beta-hemolytic streptococcus 89
Betrixaban 806
special note on 806
Bezafibrate infarction prevention 691
Bi-atrial myxoma 915, 916, 920, 931
Bifascicular block 716
Bilirubin
direct 28
indirect 28
Bioabsorbable drug-eluting stent 503
Bioabsorbable vascular scaffolds 423, 561
Biodegradable 510
polymer 508
Biolimus 491
Biolinx biocompatible polymer 563
Biological prostheses, types of 595
Biomarker measurement 600
Biomatrix flex stent 460
Biomrler testing, role of 414b
Bioprosthetic heart valves 591
Bioprosthetic valve 594596
Bioresorbable vascular scaffolds 489
BIP See Bezafibrate infarction prevention
Birth control 194
Birth defects, congenital 307
Birth prevalence rates 309
Bisfariens pulse 35, 143
Bivalirudin 423
Blade and balloon dilatation atrial septostomy 334
Bleeding 799, 803
complications 821
diathesis 563
parameters 18
Blind-spots exist 940
Blood
cholesterol 377
glucose level 892
group match 602
pressure 37, 59, 82, 359, 479, 656f, 676, 677, 953, 955
ambulatory 655
basic concepts 37
control of 449
diastolic 37, 662, 953, 954
elevated 782
high 641
homeostasis 660
levels, reduces 660
measurement 37
measurement, sources of error in 37t
monitoring 426
normalization of 671f
regulation 654f
variability 655
tests 815
transfusion 432
urea nitrogen 803
Blue nevus 920
Blue toe syndrome 561
Blurred vision 18
BMI, classification of 21t
BMP See Bone morphogenic protein
Body mass index 76, 369, 479, 776, 819, 954, 955
Body surface area 866, 869, 871
Body weight 819
Bone
formation 155
morphogenetic protein 156
receptor 188
signaling 156
Borg scale of dyspnea, modified 7t
Borg scale, modified 6, 7t
Bosentan 195
Bouillaud's sign 39
Brachiocephalic vein 565
Bradyarrhythmia 13, 430, 715
Bradycardia 67, 838
Brain natriuretic peptide 70
levels of 816
prohormone of 157
Branch pulmonary artery stenosis, dilation of 339
Branham's sign 57
Breast 927
Breath, shortness of 6, 64
Breathing exercises 975
Breathing techniques 951
British Regional Heart Study 360
Broadbent sign 39
Brockenbrough sign 34
Bromocriptine, role of 846
Bronchial asthma 6, 8, 132
Brown pigmentation 23
Brugada's syndrome 13
Buerger's disease, prevalence of 559
Buffalo milk 962
Bundle branch block
induced cardiomyopathy, left 238
left 32, 46, 71, 72, 213, 530, 744f
right 32, 39, 101, 413, 744f
Bypass surgery 459, 534
C
Cabergoline, role of 846
CABG See Coronary artery bypass graft
CAC See Coronary artery calcium
CAD See Coronary artery disease
Café au lait spots 23
Calcific aortic stenosis 862f
Calcification 155
Calcium 101
antagonists, role of 656f
channel blockers 181, 193, 194, 198, 400, 451, 452, 678, 740, 833
phosphorus product 157
Calf swelling 815
Caloric restriction 777
Canadian Cardiovascular Society 4
functional classification of angina pectoris 3
severity in atrial fibrillation scale 4, 5b, 5t
Canagliflozin Cardiovascular Assessment Study 778
Cancer, adrenocortical 920
Capillary pulsations 144
Carbamazepine 820
Carbohydrates 961t, 963
Carbon monoxide 976
Carbonyl compounds 976
Carboxyhemoglobin 21
Carcinoid 146
disease 98
CARDIA See Coronary artery risk development in young adults
Cardiac amyloidosis 286, 287
Cardiac angiosarcoma filling right atrium 909f
Cardiac arrest 740
survivors of 720
Cardiac arrhythmias 10, 956
Cardiac biomarkers 239, 395, 414, 446, 814, 816
Cardiac catheterization 106, 158, 159, 922
Cardiac chamber 919t
dimensions 869t, 871t
quantification in adults 883
Cardiac computed tomography scan 240
Cardiac cycle 860
Cardiac death 499
composite of 535
Cardiac defects, specific 324
Cardiac defibrillators, implantable 259
Cardiac diseases 63
Cardiac disturbance syndrome 556, 667
Cardiac dyspnea 7
Cardiac electrophysiological studies 714
Cardiac electrophysiology 709, 714, 735
evolution of 711
technical manager 735
technologist 735
Cardiac enzymes 239, 396
Cardiac exam, abnormal 13
Cardiac failure, congestive 25, 65
Cardiac fibroma 907, 907f
Cardiac glycosides 242
Cardiac imaging 267
Cardiac implantable electronic device
implantation, survey of 733f
reused 765
use of 764
Cardiac index 193
Cardiac injury 236
Cardiac interventions 343
Cardiac involvement 617t, 1002
Cardiac lesions, congenital 856
Cardiac loop recorder
external 79
implantable 79
Cardiac lymphoma, primary 910, 910f
Cardiac magnetic resonance 232, 250, 267, 1004
carries 1004
imaging 234, 239, 267, 268f
Cardiac masses, differential diagnosis of 905b
Cardiac myxoma 902, 905, 909f, 910, 913, 917, 918, 922, 927t
clinical features 915
clinical presentation of 927t
constitutional symptoms 915
diagnostic evaluation 921
echocardiography 921
histology 914
histopathology of 915f
history 913
immunohistochemical features 915
morphology 913
postmortem description of 913
symptoms of 918t
Cardiac neoplasms, primary 931
Cardiac pacing 764
Cardiac percussion 43
Cardiac phenotype, primary 233
Cardiac rehabilitation 434, 480482
Cardiac Rehabilitation Program 434
core components of 482f
Cardiac resynchronization therapy 206, 208, 242, 739, 746, 764, 866
devices 732
Cardiac rupture 758
Cardiac sarcoidosis 262, 264f, 265f, 268, 740
Cardiac signs 623
Cardiac silhouette 43
Cardiac surgery 569
landscape of 580t
Cardiac symptoms 623
Cardiac syncope 13
Cardiac systole 32
Cardiac tamponade 295, 876, 877
cause of 1002
management of 301fc
Cardiac toxicity 236
Cardiac transplantation
status of 599
underuse of 214
Cardiac troponins 397, 467
Cardiac trop-T/I tests 70
Cardiac tuberculosis 262, 268
Cardiac tumor 899, 901, 913
classification 903
clinical features of 904t
clinical manifestations of 904
diagnostic evaluation 905
epidemiology 901
history 901
malignant 905t
primary 909
primary 901, 901t, 902, 902t, 913, 922
surgery for 926
timeline in 901t
Cardiac valve surgery 571
Cardiobacterium 163
Cardio-facio-cutaneous syndrome 20
Cardiogenic shock, risk of 399
Cardiological Society, statements of 694t
Cardiology 692
clinical studies in 993
clinical trials 997
general survey in 22f
interventional 443, 489
Cardiomyopathy
alcoholic 234
induced 231
anthracycline induced 236
arrhythmogenic right ventricular 208, 237
dilated 55, 78, 80, 229, 232, 238, 239, 242, 244, 256, 263, 617b
doxorubicin-induced 236
Cardioplegic arrest 928
Cardiopulmonary
bypass 347, 573, 580, 834
stress testing 600
Cardiothoracic surgery 347
Cardiotoxicity 237
Cardiovascular death 967
Cardiovascular disease 62, 77, 115, 203, 204, 251, 391, 411, 438, 445, 473, 478, 481, 641, 651, 658, 661, 706, 757, 772, 782, 831, 877, 887, 917, 951, 954, 972, 984, 986, 987, 994
burden 966
control policies/programs 391
prevention of 966, 967
primary prevention 974
risk modification/reduction 973
risk prediction models 969
risk reduction 985
roadmaps 986
secondary prevention of 984, 956
settings-based interventions 983
severe 563
strategies 967
Cardiovascular effects, opposing 654f
Cardiovascular event, risk for fatal or nonfatal 971f
Cardiovascular health care quality 443
improvement programs 439, 440, 443
Cardiovascular hemodynamics 853
Cardiovascular magnetic resonance imaging 888, 889, 889b, 890, 894
Cardiovascular malformations 20
Cardiovascular mortality 979
Cardiovascular outcome results 778
Cardiovascular professionals 732
Cardiovascular risk
factors 968
reduction 691t
Carditis 127
acute 117
Carey-Coombs murmur 121, 128
Carney complex features 920b
Carney syndrome 920
Carotid anatomy, common 549
Carotid angioplasty, safe 548
Carotid artery
common 549, 557, 618f
internal 549, 557
patency of external 549
stenting 547
guidelines for 547b
tenderness 610
Carotid dance 67
Carotid interventions 549
Carotid intima media thickness 368, 892, 972
Carotid plaques 751
Carotid pulse 28t, 30f, 143
Carotid sinus 716
hypersensivity 13
massage 741
Carotid stent technique 549
Carotid ultrasound 972
Case control studies 994
Catecholamine excess 11
Catheter ablation 269
procedures, indications for 723
Catheter directed intra-arterial
thrombolysis, goals of 561
thrombolytic therapy
indications of 561
technique of 561
Catheter directed thrombolysis 824
therapy 565
Catheter-based angiography, conventional 548
CCTA See Coronary computed tomography angiography
Cell
death 428
design 496
mediated rejection 604
Cellular composition 922
Central aortic blood pressure 658, 678f
Central cyanosis 26t
Central pulse contour, normal 33f
Central vein occlusion 563, 565
Central venous
catheterization 813
occlusions 565t
pressure 28, 240
estimation of 28
Cerebral signs 623
Cerebrovascular accident 179, 535, 563, 771
Cervical softening leading 837
Chagas cardiomyopathy 207
Char syndrome 20
Charcoal filtration 752
Chest 18
computed tomography 1004
deformities 38t
discomfort 9
pain 9, 64, 233, 420422, 907
clinical classification of 64t
mild 130
nitroglycerine 426
typical 71, 71fc, 72fc
roentgenogram 1004
wall pains 10
X-ray 239
CHF See Congestive heart failure
Chikungunya 880
disease 879
Chimney grafts 550
Chitra heart valve 596
Cholesterol 778
and recurrent events 779
components of 388
controversy and media hype, recent 962
embolization 799
Cholesteryl ester transfer protein 691, 774
Chordal rupture 56t
Chronic kidney disease 76, 209, 224, 395, 579, 656, 667, 695, 697, 704
Cirrhosis 797
CKD See Chronic kidney disease
Clarithromycin 820
Clopidogrel 401, 408, 422, 427, 450, 752
Clubbing, causes of 26t
CMRI See Cardiovascular magnetic resonance imaging
Coanda effect 53, 54f
Coarctation aorta, severe discrete 338f
Coarctation segment, balloon dilation of 338f
Coarctation, severe 339f
Coarctoplasty 549
Cobalt chromium 508
alloy 491
everolimus-eluting stents 456
Cold clammy sweat 65
Collaborative atorvastatin diabetes study 779
Collagen vascular disease 188
Collateral superficial veins 815
Color Doppler echocardiography 856
Combination therapy 182, 196, 808, 810
with antiplatelet 808
with oral anticoagulants 808
Combined mitral stenosis/mitral regurgitation 573
Comelia de Lange syndrome 20
Commissurotomy, open 112
Commisural fusion 118
Common carotid lesion, left mid 610
Complement fixation test 611
Complete AV block, incidence of 739
Complex ablation procedures 713
Computed tomography 82, 263, 298, 807, 816
abdomen 555f
angiogram 349f
angiography data 892
brain 79f
coronary angiography 75f, 468
indications of 74t
pulmonary angiography 816
scan 282f
Concomitant coronary disease, detection of 250
Conduction defects 399
Conformité européenne 526
Congenital heart disease
birth prevalence of 311t, 313t
clinical spectrum of 322
complex 343
epidemiology of 307, 309
grown-up 323
major 311
management of grown-up 183
minor 311
prevalence of 311, 312t, 325t
prevention of 314, 779
risk factors for 308
significant 311
simple 323t
surgery for 347
types of 312
Congestive heart failure, stage of 65t
Conn's syndrome 679
Connective tissue 295
disease 82, 172, 187, 188, 278
disorders 19, 232, 278, 740
Conner's sign 43
Consciousness, transient loss of 78, 78fc
Consensus documents, publication of 882
Constrictive pericarditis 279f, 876
chronic
epidemiology 296
etiology 295
management 297
pathophysiology 296
presentation 296
developing 1006
epidemiology 296
etiology 295
management 297, 298fc
pathophysiology 296
presentation 296
Contraception 184
Cooing-dove/seagull murmur 52
Cor triatriatum 98
Corevalve prosthesis 527
Corevalve revalving system 527
Coronary angiogram 413
Coronary angiography 72, 429, 468
conventional 389
role of 404
Coronary angioplasty and stenting 616
Coronary arteriography 239
Coronary arteritis 238
Coronary artery 73f
aneurysm 389
anterior descending 455
bypass surgery 534
calcification 538
calcium 695, 697, 972
dissection 266
embolism 845
intima media thickness 695
left main 908
occlusion, site of 73f
right 73, 467, 578, 923f
risk development in young adults 963
severe 619f
spasm 266
stenosis 887
surgery study 447
Coronary artery bypass graft 144, 390, 404, 406, 448, 456, 458, 470, 474, 478, 532, 533, 539, 576, 580, 767, 891, 955
emergency 577, 578
evaluation 891
minimally invasive 584, 584f
off-pump 580
on-pump 580
versus off-pump 581
reoperative 585
timing of 406
Coronary artery disease 25, 62, 63f, 71, 72, 72, 209, 239, 248, 281, 386, 387, 387f, 389391, 398, 399, 445, 498, 506, 564f, 565, 576, 687, 694, 749, 750, 758, 772, 878, 887, 894, 894b, 955, 974
atherosclerotic
obstructive 390, 469
process related 387
classification of 387
distribution of 404
multivessel stable 475
nonatheromatous 388
nonobstructive 391, 469
premature 387f, 391, 878
prevalence of 473, 764
recanalized 266
risk factors for 365, 576t
severe 540t, 541
single vessel 466
complications 470
epidemiology 466
incidence 466
investigations 467
natural history 467
risk factors 466
treatment 468
treatment of multivessel stable 473
Coronary artery stent 490t
evaluation of 891
Coronary calcium score 383
Coronary catheter angiography 893
Coronary computed tomography angiography 389, 888891, 894
comparison of 890
Coronary cusp, aortic aspect of right 906f
Coronary disease 453
early 229
Coronary events after discharge
from hospital, sprevention of 441
secondary prevention of 441
Coronary heart disease 207, 358, 358f, 360, 365, 382t, 479t, 481, 509, 641, 660, 661, 692, 945, 961
burden of 357
conditions of 359
developmental origins of 361
epidemiology of 357
genetic epidemiology of 361
global burden of 357
life course influence of 362
number of 358f
prediction of 361
prevalence of 357
prevention and control of 362
risk factors for 366t
treatment 478
gaps in 362
Coronary intervention
complex 532
radial versus femoral access for 405
Coronary magnetic resonance imaging 890, 891
Coronary revascularization 403, 429
Coronary sinus catheter 730f
Coronary stenting 470
Coronary surgery, future of 587
Coronary syndrome
acute 72, 213, 215, 237, 266, 386, 395, 396t, 405t, 438f, 440442, 445, 466, 576, 693, 703, 752, 760, 778, 809, 809f, 810, 878, 891
risk of acute 808
Coronnium 493, 497
Corrigan's pulse 34, 143
Corrigan's sign 67, 143
Corticosteroids 614
dosing of 1006t
use of 1006
Costello syndrome 20
Costochondritis 64
Cough 12
chronic 12
syncope 13
Coxsackie virus 233
C-reactive protein 370, 694, 773
Creatine kinase 233, 707
Crossing mitral valve 519
CRP See C-reactive protein
CRRAFT See Rheumatic atrial fibrillation trial
CRT See Cardiac resynchronization therapy
Cui formula 107
Cushing's syndrome 676
Cutting balloon angioplasty 561
CVD See Cardiovascular diseases
Cyanosis 17, 21
different types of 25t
Cyanotic heart
congenital 17
disease, adult congenital 66
Cyclic vomiting syndrome 6
Cyclophosphamide 295, 614
Cyclosporine 295, 820
Cytochrome P450 system 798
Cytotoxic agents 614
D
Da Costa's syndrome 10
Dabigatran 751, 805
etexilate 800, 802, 819
DALY See Disability adjusted life years
Danon disease 233, 249
Davie's disease 279
DBP See Diastolic blood pressure
De Musset sign 143
de Novo lesion, single 499
Debulking devices 561
Decubitus 19
Deep sternal wound infections, risk of 578
Deep vein thrombosis 431, 565, 795, 797, 813
acute 818fc
management of 815
Defibrillators 767
Deformity aortic regurgitation 125
Degenerative and humanmade disease 77
Degenerative aortic
stenosis 446
valve disease 160, 571
Degenerative diseases, delayed 77
Degenerative heart disease, incidence of 154
Degenerative mitral valve disease 161
Degenerative valve disease 153, 155, 156
epidemiology 153
genetic in 156
Degenerative valvular heart disease 153
Dengue 879
Dense calcification 548
Depression 947, 951
management of 449
presence of 956
Desmopressin 805
Device therapy 213, 216
Diabetes 224, 229, 622, 651, 692, 693, 945
and cardiovascular disease
epidemiology 771
risk factors for 773
screening and prevention 776
event lowering in 691
interventions and complications study, epidemiology of 778
management 479
mellitus 77, 209, 221, 232, 367, 449, 460, 576, 579, 797, 951, 953955, 980
prevalence of 771
trials, non-insulin-dependent 779
prevalence of 772
prevention program 787
Diabetic atherogenic dyslipidemia 698
Diabetic dyslipidemia 773
treatment of 698
Dialysis, chronic 797
Diaphoresis 14, 415
symptoms of 14
Diastolic dysfunction 64, 188, 221, 247
demonstrate 221t
grading of 273
Diastolic murmur
early 53, 56
mid 56
Diastolic pressure 37
Diastolic velocity, mitral inflow
early 870, 871
late 870, 871
Dicrotic anacrotic pulse 35
Dicrotic pulse 35
Diet 359, 370, 449, 786
and cardiovascular disease 960
prevention 962
Dietary carbohydrate, assess 775
Dietary changes 651
Dietary fat 961
advice 962
Dietary habits 775
Dietary principles 977
Dietary salt restriction 960
Diffuse multiple stenosis 559
Digital subtraction angiography 563
Digoxin 107, 730f, 740, 752, 820
toxicity 68
Dihydropyridine 452
calcium channel-blocking drugs 252
Dilated cardiomyopathy, genetic causes of 233
Diltiazem 452, 820
Dipeptidyl peptidase 779
Disability 652
adjusted life years 835, 966
Discrete subaortic stenosis 325
Disease classification 609
Disease reactivity 615
Disease registries 998
Disopyramide 255, 731
Disproportionate sinus tachycardia 236
Distal brachiocephalic trunk lesion 610
Diuretics 14, 108, 222, 242
Dizziness 18
DM See Diabetes mellitus
Dobutamine 252
stress
cardiac MRI 424
echo 424
echocardiography, low-dose 858f
Docetaxel 491
DOE See Dyspnea on exertion
Donor harvesting after cardiac death 600
Donor organ
preservation of 604
transport of 604
Dopamine 252
Doppler echocardiography 104
conventional 856
Dorsalis pedis 33
Double-balloon technique 25, 110, 111, 313
Double-chambered right ventricle 325
Double-outlet right ventricle 20, 25, 313
Double-valve replacement 572
Doxorubicin 236
Dressler's sign 43
Dressler's syndrome 431
Dronedarone 802, 820
Drug therapy, specific 194
Drug utilization studies 991
Drug-coated balloons 558, 561
Drug-eluting
agent 490
stent 405, 474, 489, 558, 561
development of 490
Drug-naïve lifestyle disease, prevalence of 950
Duchenne dystrophy 233
Duchenne muscular dystrophy 19, 233, 242
Duct-dependent circulations 345
Duke activity status index 5t
Dumbbell appearance 916f
Duroziez's murmur 34
Duroziez's sign 68, 130, 143
Dysfunctional high-density lipoprotein 370
Dysglycemia 360, 369t, 773
Dyslipidemia 221, 229, 367, 369t, 450, 651, 679, 685, 687, 694f, 702, 703, 774, 785, 945, 952, 969, 980
epidemiologic studies 688
genetic studies 688
interheart study 688
international data 688
management of 692, 702, 703, 943f
pathogenesis 687
Dyspepsia 400
Dysplastic pulmonary valve 335f
Dyspnea 6, 8, 9, 11, 16, 64, 130, 192f, 223, 251, 916, 929
assessment of 6
chronic 223
exertional 7
formal measurement of 6
inspiratory 7
isolated 446
pathological 6
severity scale of 7t
Dyspneic baby 16
Dysrhythmias 65
Dystrophin 238
gene 242
E
Ebstein's anomaly 42, 323, 328
Ebstein's sign 43
Ecarin clotting time 803
Echnical skills 540t
Echo Doppler study 239
Echocardiographic diastolic function 237
Echocardiographic imaging 874
Echocardiography 102, 139, 144, 239, 250, 267, 298, 414, 467, 817, 853, 865, 882, 885, 918t, 1004
advent of 100
cardiac chamber quantification 882
evolution of 853
performing personnel, training of 884
role of 118, 745
scoring system 516t
training in 863
Echolucent plaques 548
Echovirus 233
Edema 12, 27
acute pulmonary 99, 102
causes of 27t
Edoxaban 802, 804, 819
Educational level 985
Edwards sapien 526
Effusive constrictive pericarditis 300, 1003
Ehler-Danlos syndromes 38
Eikenella 163
Eisenmenger's complex 176
Eisenmenger's physiology 177
Eisenmenger's syndrome 12, 54, 146, 176, 177, 177t, 178t, 179184
frequency of 177t
Ejection click 53
Ejection fraction 204, 866, 868
Ejection sounds 48
Ejection systolic murmur 53, 55, 56, 58
Elective surgery 194
Electrocardiogram 30f, 7174, 78, 80, 82, 221, 239, 263, 396, 413, 467, 815
Electrocardiograph 744f
Electronic nicotine delivery systems, use of 976
Electrophysiological study
in pediatric patients, role of 727
role of 714722
Electrophysiology
development of 728
interventional 730
research activities in 729
Ellis-Van Creveld syndrome 20
Embolic protection device 549
use of 548
Embolization therapy 343
Emerging economics 946
Emery-Dreifuss muscular dystrophy 233
Empagliflozin 994
Endarterectomy 583
Endarteritis 325
End-diastolic pressure 64
Endocardial calcification 277f, 281f, 283f
Endocardial hypoperfusion 64
Endocardial tuberculosis 1003
Endocarditis 64, 328, 836, 840
Endocrine
diseases 232
disorders 19
Endoleak, types of 552f
Endomyocardial biopsy 234, 239, 241
Endomyocardial calcification 282f
Endomyocardial fibrosis 276f, 278, 279, 281f, 877
severity of 877t
Endoscopic harvest 583f
Endoscopic vein harvesting 582
Endothelial cell proliferation 189
Endothelial dysfunction, role in 773
Endothelial function 155
Endothelial progenitor cells 773
Endothelialization 507
Endothelin antagonist therapy-5, Bosentan randomized trial of 182
Endothelin pathway 196
Endothelin receptor antagonists 182, 195
Endothelium 784
role of 661
Endovascular aortic repair 551
Endovascular intervention 554, 561
and surgery 629
Endovascular management 553
Endovascular revascularization 559
Endovenous laser therapy 564, 565t
Enoxaparin 423, 426
Eosinophilic endocarditis 241
Epidural analgesia 838
Epiphyseal calcification 833
Eplerenone 434, 682
Epoprostenol 196
Erectile dysfunction, complex 564f
Eruptive xanthoma 24
Erythema marginatum 24
Erythrocyte sedimentation rate 72, 82, 626
high 618
Erythromycin 820
Erythropoiesis stimulating agents 216, 813
ESR See Erythrocyte sedimentation rate
Establishing standard treatment guidelines 937
Estimated glomerular filtration rate 76, 80, 600
Estrogen treatment 813
Ethanol 229, 233
Ethics committee 949
European Association for Cardiothoracic Surgery 110, 526, 577, 578, 579
European Medicine Agency 490
European Registry of Congenital Anomalies 313
European Registry on Pregnancy and Heart Disease 835
European Society of Cardiology 110, 172, 192, 193t, 195t, 203, 526, 533, 577579, 693, 702, 783
classification of acute pulmonary embolism 814t
guidelines 122, 767, 834
score 447
European surveillance of congenital anomalies 322
Everoflex 504
Everolimus 491, 510
Everolimus-eluting stent 460, 494, 498, 502, 507
implantation 459
Ewart's sign 43
Exercise stress test 467
Explanted permanent pacemakers, reuse of 746
Extracellular fluid 660
Extracorporeal membrane oxygenation 428
Extrafascial harvest technique 583
Extra-pulmonary tuberculosis 1002
F
Fabry's disease 146, 233, 258, 278, 861
Faintness 18
Fallot's physiology 66
Familial cardiomyopathy 238
Familial dilated cardiomyopathy 241
Familial hypercholesterolemia 692, 704
Familial myxoma 920
Family screening guidelines 249
Fascicular block, left anterior 413, 446, 744f
Fascio-scapulo-humeral muscular dystrophy 233
Fasting blood glucose 954, 955
Fasting glucose 968
elevated 782
impaired 694, 772
Fasting plasma glucose 369, 773
Fat
quality of 962
types of 961t
Fatal, predicted risk of 380
Fatigue 18, 951
Fatty acid 774
essential 778
oxidation inhibitor 434
FBG See Fasting blood glucose
Femoral arteriotomy 550
Femoral artery
common 558, 560
superficial 558, 560
Femoral endarterectomy 556
Femoropopliteal lesions 559, 560
Femoropopliteal occlusive disease 558
Fenofibrate intervention 691
Fetal
anticoagulation 833
apnea 838
cells 844
chimerism 844
echocardiography 314
mortality 834
programming 372
Fever 623
Fibrate 690
therapy 691t
Fibrillation 724, 725
Fibrin specific agents 417
Fibrinogen 388, 389, 803, 969
Fibrinolytics 417
Fibrocalculous pancreatic diabetes 772
Fibroma 903, 907, 926
Fibromuscular disease 670
Fibromuscular dysplasia 554, 672, 677
Fibromyalgia 10
Fibrosarcoma 909, 932
Fibrosis 845
apical 283f
secondary to 1003
Fibrotic thickening 279
Fibrous histiocytoma, malignant 910
FIELD See Fenofibrate intervention and event lowering in diabetes
Filbert or watch-glass nail 26
Financial burden, reducing 215
First indigenous coronary stent, development of 490
Fish-mouth appearance 515f
Fixed-dose combination, safety of 779
Flecainide 730f
Flexibility 497
Flexinnium 498
coronary stent 498
Fludeoxyglucose-positron emission tomography 889
Fludrocortisone suppression 680
Fluorodeoxyglucose positron emission tomography 613
Fluoroscopic fusion 859
Flutter 724, 725
FMD See Fibromuscular disease
Focal angiographic stenosis 563
Folic acid 314
Fondaparinux 403, 427
Fontan operation 329
Food safety and standards authority 961, 985
Formaldehyde 976
Fossa ovalis 913
membrane 909
Fractional flow reserve 405, 475, 539, 667
measurement of 448
Fractional shortening 232
Framingham criteria 204
Framingham risk score 696
Free fatty acids 774, 785
Fresh frozen plasma 804, 805
Friedreich's disease 233
Friedreich's sign 43
Fryns syndrome 20
Fundamentals and learning curve 536
G
Gadolinium-diethylenetriamine pentaacetic acid 240
Gaertner's method 29
Gallavardin phenomenon 53, 129
Gamma-glutamyl transferase 157
Gas vaccine 94
development 95t
Gastroepiploic artery, right 583
Gastrointestinal bleeding 603
Gene environment interactions 361
Gene
mutation of 784
pool 945
therapy 561
Genetic in salt homeostasis, role of 661
Genetic mutations 254
Genetic studies 611
Genetic testing strategies 249
Gerbode's defect 31
Germ cell tumor 904
Gestational age, small for 776
Gestational diabetes mellitus 777
Giant atria 116
GLAGOV randomized clinical trial 690
Global adult tobacco survey 975
second report of 370
Glomerular filtration rate 678
Glucocorticoid 629, 678
remediable aldosteronism 679
genetic test for 682fc
Glucose tolerance, impaired 694, 772
Glycation-related vascular endothelial injury 773
Glycemic control 679
Glycogen storage disease 233, 278
Gorlins formula 107
Gorlins syndrome 907
Gower's sign 19
Graham Steell murmur 179
Granuloma 268
Granulomatous caseation 1002
Granulomatous inflammation 622
Granulomatous myocarditis 262, 266, 266fc, 267, 268
Great arteries 177
congenitally corrected transposition of 323, 329
dextro-transposition of 348
transposition of 77, 177, 329
Greene's sign 43
Grocco's cardiac sign 43
Gross domestic product 938
Guiding drug therapy 721
H
Hakki's formula 107
Hall-Hittner syndrome 20
Hamman's sign 50
Harvested cadaveric organ 605
Has-bled scoring system 797t
Hazard ratio 972
HDL See High-density lipoprotein
Head up tilt test 78
Headache 18
Health
benefits 949
insurance schemes 937
Healthcare
bureaucracy 987
environment 946
facilities 885
improvement 439
policies 483
primary 937
resources 937
Healthy fat substitute 963
Healthy plate 980f
Heart 913, 929, 930, 930t, 932
against cardioplegic arrest studies 581
anomalies, congenital 20t
autopsy specimen of 913f
beat, irregular 77
cardiac tumor of 913
congenital 187
defect, congenital 349f
dilated 13
lung transplantation 183
muscle diseases 273
protection study 779
rate, irregular 398
rhythm disorders, treatment of 734
team 577
type fatty acid binding protein 82
Heart block 65
complete 257, 712f
types of 78
Heart catheterization
left 82
right 82, 187, 192, 240, 600
Heart disease 74, 82, 838
care, congenital 315
congenital 171, 172, 188, 209, 211, 220, 307, 310313, 317, 322, 324b, 324t, 332, 347, 601
incidence of 837
left 171
structural 921
Heart failure 11, 76, 76t, 77, 203, 206211, 220, 224, 750, 907, 967
acute 78, 78fc, 208, 422
decompensated 75, 207
care 217
causes of 204
chronic 208, 222
clinical conundrum of 208
congestive 15, 65, 98, 128, 231, 262, 353, 399, 540, 556, 572, 730f, 797, 813, 836, 572, 730f, 929
devices 767
diagnosis of 994
epidemiology of 203
increasing burden of 210, 211
management 207, 208, 208t, 209f, 213, 217b, 221
observational 750
outcome 203
acute 215
right 100
scenario of 206
severe 5, 605
trends in 207
with biomarkers, triaging of acute 76t
with preserved ejection fraction 209
with reduced ejection fraction 209
Heart sound 44, 515
diastolic 44
fourth 48
late 44
mid 44
second 45
systolic 44
third 47
types 44
Heart transplant 242, 243, 259, 599
categories of 604
classical indications of 601
number of 599
Heart valve 89
surgery 574
program, development of 574
Heim-Kreysig sign 39
Hemangioma 904, 926
Hematemesis 132
Hematologic disorders 188
Hemochromatosis 23, 233, 236, 278, 284
Hemoclot thrombin inhibitor assay 803
Hemodialysis 752, 805
Hemoglobin 82
Hemolytic anemia 171, 916
chronic 188
Hemopericardium 523
Hemoptysis 8, 12
cardiac causes of 12, 12b
management of 183
Hemorrhage, intracranial 417, 431, 807
Hemorrhagic fever 879
Heparin 408
Heparin-induced thrombotic thrombocytopenia 561
Hepatic disease, chronic 797
Hepatic involvement 601
Hepatic vein 297
Hepatoma 57
Hereditary hemochromatosis 236
Heritable pulmonary arterial hypertension 195
Heterotaxy syndromes 319
HFPEF See Heart failure with preserved ejection fraction
HFREF See Heart failure with reduced ejection fraction
HHS See Helsinki heart study 691
Hill's sign 68, 130, 144
His bundle electrography 712f
His-Purkinje system 719
Histidine-tryptophan ketogluatarate 604
Histiocytoid cardiomyopathy 903
HIV See Human immunodeficiency virus
Hockey stick appearance 103f
Holt-Oram syndrome 20
Homan's sign 814
Homemade bioprosthetic valves 573
Homocysteine 371, 388, 702
Homocystinuria 19
Homograft valves 594
Hormone, adrenocorticotropic 679
HPA See Hypothalamus pituitary adrenal
Human development 89
indices 91
Human disease 149
Human immunodeficiency virus 187, 233, 299, 1006
associated cardiomyopathy 238
associated infections 299
infection 172, 188
negative tubercular 1006
protease inhibitors 820
test 191
Human population, migration of 945
Hunter-Hurler syndromes 38
Hybrid procedures 550
Hydrogenated vegetable oil, type of partially 961
Hydroxychloroquine 295
Hydroxymethylglutaryl coenzyme reductase inhibitors 157
Hyperaldosteronism, confirmatory tests for 682fc
Hypercholesterolemia 774
prevalence of 692f
Hypercoagulable states 389
Hyperdynamic apex 41
Hyperdynamic circulatory state 230
Hypereosinophilic syndrome 278, 284
Hyperglycemia 773
Hyperhomocysteinemia 387, 388
Hyperkalemia 740
Hyperkinetic pulmonary arterial hypertension 55t
Hyperparathyroidism 232
Hyperplasia 784
Hypertension 25, 46, 209, 210, 229, 238, 369, 383, 449, 610, 623, 639, 643, 647, 651, 660, 669f, 774, 782, 786, 945, 951953, 969, 981
accelerated 555
and salt intake 660
awareness 652
control 645
meta-analysis of 646f
treatment 654
burden of 645
comorbidities 652
control of 555, 653, 653b
epidemiology of 661
malignant 555
management 479
of secondary 676
portal 171, 187, 188
prevalence of 641, 642t644t, 774
recent trends in 641
refractory 555
secondary 676, 676t, 677
severe 672f, 676
tests for evaluation of 80t
treatment of 786
uncontrolled 667
Hyperthyroidism 232, 721
Hypertriglyceridemia 774
Hypertrophic cardiomyopathy 20, 25, 30, 53, 78, 80, 231, 246, 248, 248, 256, 260, 266, 732
denetics of 248
management of 259
reveals 247f
Hypertrophic obstructive cardiomyopathy 34, 39, 53, 60, 246, 854f
Hyperviscosity syndrome 18
erythrocytosis, symptoms of 18b
Hypervolemia 31
Hypodense 681
Hypoglycemia 779, 984
Hypokinesia 879, 880
Hypoparathyroidism 232
Hypoplastic left heart syndrome 20
Hypotension 9, 237, 426
Hypothalamus pituitary adrenal 954
Hypothermia 349f
Hypothesis 64
Hypothyroidism 232, 299, 676
Hypoxemia, stimuli of 17
Hypoxia 184, 188
I
Ibutilide 731
ICD See Implantable cardioverter defibrillator
Idarucizumab 803, 805, 824
Idiopathic cardiomyopathy 204
Idiopathic dilated cardiomyopathy 229, 241
Idiopathic hyperaldosteronism 679
Idiopathic hypertrophic subaortic stenosis 246
Idiopathic pulmonary
artery hypertension 171, 180, 187
hypertension 82, 189t
Idiopathic restrictive cardiomyopathy 278, 285
IFG See Impaired fasting glucose
IGT See Impaired glucose tolerance
IHA See Idiopathic hyperaldosteronism
Iliac angioplasty 556
Iliac artery
angioplasty of 616
common 560
external 560
Iliac crest 783
Iliac stenosis 559
Iliac stenting 556
Immune cells 784
Immune modulating therapy 846
Immune modulation 785
Immune suppressant properties 131
Immunization against rubella 314
Immunosuppressive drugs 295
Implantable cardioverter 729
defibrillators 206, 208, 242, 254, 269, 739, 764, 866, 892
Implantable electrical devices 722
Implantable loop recorders 743
role of 745
Incessant supraventricular tachycardias 727
India designed valve 596
India heart watch 646
Indian Academy of Echocardiography 863
Indian Atherosclerotic Research Study 388
Indian cardiac surgeons 583
Indian consensus statements on lipid management 693
Indian coronary artery bypass grafting 586
Indian Council of Medical Research 94, 153, 360, 772
Indian Diabetes Risk Score 776
Indian Genetic Studies 389t
Indian Heart Rhythm Society 764
Indian Information Technology 947
Indian Society of Electrocardiology 764
Indian stent 196, 491, 491t, 509
Indigestion 9
Indolimus 493, 500, 504
G registry 500
Induction therapy 603
Infant mortality rate 77
Infarct related artery 417
Infection 8
chronic 360, 652
prevention 194
Infective endocarditis 25, 833
Infiltrative disease 740
Infiltrative disorders 278
Infinnium 499
pes 498, 501
Inflammation 156, 956
markers of 156
mediators of 156
Inflammatory cells infiltrate 241
Inflammatory disease, chronic 704
Inflammatory markers 972
Inflammatory mediators, levels of 956
Inflammatory myofibroblastic tumor 904
Influenza
vaccination 449
virus 233
Information technology, development of 947
Informed consent 993
Infra-renal
aorta, occlusion of 669f
aortoiliac occlusion 559
Inherited thrombophilia 813
Inoue balloon technique 514, 517, 838
Insignia 493
Insulin
nonmetabolic actions of 785
resistance 784, 976
pathophysiology of 784
signal transduction 784
Integrated disease surveillance project 692
Intense competitive sports 248
Intensive care units 573, 753
Intensive coronary care units 425
Interatrial septum 913, 916f, 919, 928
dilatation of 519
lipomatous hypertrophy of 909f
Intercostal space 53, 54
Interferon gamma 1005
Interheart risk score 382, 382t
Interheart study, implications of 372
International Diabetes Federation 360, 772, 782784
International Guidelines on Coronary Artery Surgery 577
International Index of Erectile Function 565
International Normalized Ratio 72, 751, 798, 801, 804, 807
International Quality Improvement Collaborative 353
International Randomized Ratio 751
International Society of Hypertension 694
Interrupted aortic arch 20
Interstitial and frank pulmonary edema 85f
Interstitial cells, proliferation of 241
Interstitial edema 845
Interstitial lung disease 188
Interventricular septal rupture 216
Interventricular septum 56, 56t, 869
disproportionate hypertrophy of 247f
involvement of 240f
Intimal-medial thickness 625
Intra-aortic balloon pump 405
Intra-atrial electrogram 712
Intracardiac myxoma 926
Intracellular triglyceride 774
Intrauterine growth retardation 832
Intravascular imaging 535
Intravascular ultrasound 546
analysis 547f
Intravenous phenylephrine 251
Intravenous saline infusion 680
Intraventricular conduction delay, chronic 716
Intrinsic system 803
Invasive cardiac electrophysiology 728
procedure 736
Invasive coronary
angiography 448
arteriography 887
Invasive procedure 193
Invasive therapy 252
Iron deficiency 184, 224
detection and correction of 214
Iron overload 229
cardiomyopathy 236
Irritable bowel syndrome 951
Ischemia 398, 721
Ischemic cardiomyopathy 204, 231
Ischemic cerebrovascular events 774
Ischemic heart
disease 46, 64, 204, 210, 466, 688, 771, 878, 918
failure, surgical treatment for 767
Ischemic mitral regurgitation 446
surgery for 586
Ischemic myocardium 858f
Ischemic nephropathy 667
Ischemic signs 623
Ischemic stroke
acute 561
risk of 797
treatment of acute 807
Ishikawa's criteria 610t, 617
Isoniazid 810
Itraconazole 820
Iung and Cormier score 105
Ivabradine 400, 453
J
Jai Vigyan mission 839
Jaipur heart watch 646
Janeway lesions 24
Japanese Ophthalmologic Society 621
Jaundice 28
Jaw pain 446
Joint British Societies 704
Jomiva balloon technique 111
Joseph mitral valvuloplasty 839
Jugular vein
external 28
internal 28, 521
Jugular venous pressure 55, 65, 68, 298
causes of elevated 29t
Jugular venous pulse 28, 28t, 275f
Jugular venous waveform 29, 30f, 32f
abnormalities in 30
Jugular waveform, clinical recognition of 30
Junctional tachycardia 67
Juvenile mitral stenosis 99, 523
Juvenile Takayasu's arteritis 555f, 556f
Juxtadiaphragmatic/juxtaceliac and infrarenal segment 635
K
Kaplan-Meier estimates of event-free survival 535f
Kaposi-Stemmer sign 27
Kawasaki disease 238
Kearns-Sayre syndrome 233
Kerala acute coronary syndrome registry 439
Ketoconazole 820
Keutel syndrome 20
Kingella 163
Kissing stents 557
Klinefelter's syndrome 19
Korotkoff sounds 34, 36, 37
Kussmaul's sign 29, 877
L
Lactate dehydrogenase 28
Lanci's sign 31
Large-scale genome-wide association study 776
Lax regulatory rules 946
LDL See Low density lipoprotein
Leflunomide 629
Left ventricle 73, 103, 104, 278, 282, 286, 855, 878, 879, 908, 915, 916, 930
dysfunction 797
restoration of 576
systolic function, reduced 148
Left ventricular 46, 860f, 866, 868t
aneurysm 585
surgery for 585
angiogram 284f
assist device 208, 214
diastolic function 871t, 883
dilatation 865
dimension relevant 866t
dysfunction 171, 453, 745, 761, 766
ejection fraction 120, 220, 231, 765, 866, 892
end-diastolic
dimension 868
dimension indexed 868
pressure 16, 65, 105, 141, 221
volume 868
endocardial calcium 277f
endomyocardial fibrosis 283f, 284f
enlargement 229
failure 427, 434
function 103, 140
impaired 540
hypertrophy 30, 80, 158, 246, 657
mass index 221
myocardium 267f
noncompaction 235
only pacing 732
outflow tract 46, 50, 53, 118, 246, 530
obstruction 247, 326
segments 857
systolic dysfunction 434
wall, posterior 854
Leiomyosarcoma 904, 909, 910
Lennox-Gastaut syndrome 997
Lentigines 920
multiple 23
Leopard syndrome 23
Leptin function 785
Leriche's syndrome 36
Lesions, specific 832
Leucocytosis 622
Leukocyte 773
infiltration 125
Levine and Harvey's inching method 44
Levine's sign 9, 19
Levonorgestrel releasing intrauterine device 184
Life-threatening
disease 163
ventricular arrhythmias 563
LIMA See Left internal mammary artery
Limb
girdle dystrophy 233
ischemia
acute 561
critical 558
Linoleic acid 977
Lipid 360
abnormalities 773
management 479
profile 954
therapy 451
Lipidology 692
Lipoma 904, 908, 926
Lipomatous atrial hypertrophy 904
Lipoprotein 371, 388
cholesterol
high-density 367, 387, 691, 693695, 702, 706, 774, 783
levels, high-density 691
levels, low-density 451
low-density 360, 367, 694, 705
genes for 388
high low density 641
high-density 369, 387, 479, 697, 955
increasing high-density 974
intermediate density 687
levels 788
low-density 387, 451, 479, 687, 693, 696, 697, 774, 954, 955
low-high density 641
non-high density 687, 696
targets of non-high density 697
Liposarcoma 909
Lithium 740
Liver
fatty infiltration of 774
function
abnormal 797
test 82, 195
LMCA See Left main coronary artery
Localized arterial obstruction 57
Loeffler's endocarditis 278, 282, 283, 284f
Lone aspiration thrombectomy 390, 469
Loop recorder, internal 78
Loviband's angle 26
Low backache 951
Low density lipoprotein, targets of 697
Low-fat dairy products, consumption of 777
Low-gray scale median 548
Low-molecular weight heparin 402, 797
Low-serum sodium 204
Lung
biopsy 82
disease 171, 188
injury, transfusion-related acute 804
scintigraphy 816
transplantation 197
LV See Left ventricular 866
LVEF See Left ventricular ejection fraction
Lymph nodes 268
Lymphocytic myocarditis 241
Lymphoma 904, 910
M
M mode echocardiography 102, 102f
Macrolides 810
Macruz index 101
Magnetic resonance
imaging 79f, 240, 807
venography 816
Malaise 623
Malarial fever 879
Male erectile dysfunction 562
Mammary artery
bilateral internal 581
left internal 457, 578, 584, 584f
Manipal-flex registry 501
Marfan's syndrome 19, 38, 67
Massive left-ventricular hypertrophy 248
Massive pulmonary embolism 561
Maternal hypoxia 837
Maternal mortality 847
rate 836
Matrix metalloproteinase 157
inhibitors 157
Maximal exercise test 6
May's sign 29
Maze procedure 255
Maze-like surgery 752
MDA See Methylenedioxyamphetamine
Means-Lerman sign 50
Mechanical and stented tissue valves 166
Mechanical heart valves 591
Mechanical prosthetic valves 798
Mechanical valve 594596
Medial fibromuscular dysplasia 672f
Mediastinal crunch 50
Mediastinal irradiation 299
Mediastinal lymph nodes 1003
Mediastinal nodes 1004f
Medical nutrition therapy 778
Medical therapeutics, manual for 941f
Medical therapy 555
Medicine, indigenous system of 937
Meditation 951
Mediterranean diet 449
Medtronic corevalve 528t
Menarche 184
Mendelian gene syndromes 20t
Mental illness 970
Meperidine 727
Mesenchymal sarcoma 909
Mesenteric artery 557
angioplasty of 616
Mesothelioma 910
Metabolic disorders 188
Metabolic panel 239
Metabolic syndrome 369, 782, 783, 784, 787, 951, 952, 982
implications of 787
management 786
Metallic commissurotomy 110, 514
technique 111
Metallic platform 510
Metastatic disease 909
Metastatic tumors 901
Metformin 779
glibenclamide therapy 779
glimepiride 779
vildagliptin 779
Methemoglobin 21
Methicillin-resistant Staphylococcus epidermidis 163
Methionine synthase 389
Methotrexate 295, 614
Methylene tetrahydrofolate reductase 389
Methylenedioxyamphetamine 954
Methyprednisolone 603
Metoprolol 427, 846
Metronidazole 810
Mexiletine 712
Microvascular complications 777
Microvascular ischemia 251
Micturition syncope 13
Mid-myocardial segments, late gadolinium enhancement of 240f
Migraine 951
Miliary tubercle 1003
Mineral 963
supplements 963
Mineralocorticoid receptor antagonists 206, 222
Minimally invasive cardiac surgery 584
Mitochondrial diseases 233
Mitochondrial myopathy 233
Mitral annual calcification 155
Mitral annular
early diastolic velocity 870, 871
late diastolic velocity 870
systolic velocity 870
velocities 870t
Mitral balloon valvuloplasty 516t
Mitral commissurotomy 142f
closed 137
percutaneous transluminar 137
percutaneous transseptal 832, 838
Mitral diastolic murmur 917
Mitral E velocity, deceleration time of 870, 871
Mitral inflow velocities 870t
Mitral leaflet
anterior 854f, 855f
posterior 102, 115
Mitral prosthetic valve endocarditis 166
Mitral regurgitation 10, 39, 50, 55, 56t, 60, 109, 153, 154, 159, 833, 918
acute 55t, 216, 428, 524
chest X-ray 160
chronic 55t, 115
echocardiographic score 106
echocardiography 160
electrocardiogram 160
etiologies of isolated 155f
genetics 160
investigations 160
isolated 138
pathogenesis 159
physical signs 160
severe 515, 524f
symptoms 160
Mitral restenosis 112
Mitral stenosis 8, 12, 20, 50, 56, 56t, 60, 98, 100, 102, 108, 116, 136, 138, 148, 153, 154, 519f, 832, 836, 837, 918
drug-induced 98
management of 109f
moderate 99
natural history of 98
pathogenesis of 98
presystolic murmur of 69f
severe 104f, 915f
severity of 136, 136t
surgical procedure for 572
symptom of 99, 107
Mitral valve 98, 109, 127, 135, 158, 514, 855, 874, 908
anatomy 158
area 103, 103f, 104, 109, 514, 515, 833, 893
Doppler evaluation of 104
planimetry of 875f
balloon dilatation 573
chest X-ray 159
clip 140
dilatation 338
disease 146, 171, 918
echocardiogram 159
electrocardiogram 159
investigations 159
leaflets 102f, 283f, 515, 519
normal 914f
pathogenesis 158
prolapse 20, 39, 55, 60, 155
repair 139, 140, 573, 586, 834
replacement 109, 139, 140, 253, 586
scoring systems 105
signs 159
surgery 137, 140, 144
symptoms 159
thickened 515f
Mitral valvotomy 111, 112, 838
closed 108, 572
open 109
Mitral valvuloplasty 112
Mixed valvular lesions 144
M-mode echocardiography 853
Molecular weight heparin 833
Mononuclear cell infiltration 845
Monounsaturated fatty acid 961, 977
Morbidity, predictors of 204
Morphine 400, 426
Mortality, predictors of 204
Moschowitz's sign 43
Mosquito-borne diseases 879
MR See Mitral regurgitation
MS See Mitral stenosis
Muehrcke's lines 27
Muller's sign 67, 144
Mullins sheath near mitral valve 522f
Multicenter studies 890
Multidetector computed tomography 82, 528
Multidisciplinary heart team discussion 528
Multi-electrode catheter 729
Multilayer flow modulator 551f
use of 550
Multinational stents 509
Multitrack technique 514
Multivessel coronary artery disease 459, 473, 539
Multivessel disease 540
management of 474
Multivessel percutaneous coronary intervention 539, 540
Multivessel treatment 475
Mural thrombus 431
Murmur 58t, 69f
classification of 50t
continuous 57
diastolic 56, 99
innocent 51
transmission of 52
Muscle weakness 18
Muscular dystrophy 740
Musical murmur 52
Musset's sign 67, 130
Myalgia 18, 623
Mycobacterial antigen 623
Mycobacterium tuberculosis 163, 267, 612, 622
Culture of 1005
Mycophenolate mofetil 614
Mycoplasma 164, 165
Myeloproliferative disorders 813
Myocardial calcification 84f, 278
Myocardial contrast echocardiography 856
Myocardial dysfunction 238
Myocardial infarction 72b, 74, 78, 299, 372, 397, 397f, 448, 474, 534, 563, 751, 759t, 761, 766, 797, 813, 845, 967
acute 9, 67, 425f, 490, 506, 688, 740, 772, 798, 889
anterior 860f
chronic 889
perioperative 577
recurrent 480
rehabilitation after 432
Myocardial infarction/death, reduction of 450
Myocardial inflammation 267
Myocardial injury 241
Myocardial insult 70
Myocardial ischemia 247, 403, 541
Myocardial oxygen 9
Myocardial perfusion
defects 887
imaging 77
Myocardial revascularization, surgical 587
Myocardial scar 766
Myocardial tuberculosis 1003
Myocarditis 64, 229, 234, 238, 740, 844
Myocardium, diffuse infiltration of 1003
Myocyte necrosis 241
Myosin binding protein C 233, 257
Myosin heavy chain 233, 241
Myositis 10
Myotonic dystrophy 233
Myotonic muscular dystrophy 233
Myxedema 232
Myxofibrosarcoma 904
Myxoid fibroadenomas 927
Myxoid sarcoma 909
Myxoma 904, 915, 917, 917f, 920, 923f, 926, 931
cells 914
distribution 919
in childhood 920
location of 918
Myxomatous mitral valve 155
N
Narcotic analgesics 426
Nasal hypoplasia 833
National Board in Pediatric Cardiology, diplomate of 352
National Cholesterol Education Program Adult Treatment Panel III 782
National Family Health Survey 359, 643
National Health and Nutrition Examination 784
survey III 972
National Health Programs 937
National Heart, Lung and Blood Institute 782
National Institute of Health Stroke Severity Scale 807
National Interventional Council 489
National Lipid Association 697t
National Program for Control of Cancer, Diabetes, Cardiovascular Disease and Stroke 383, 776
National Programme for Prevention and Control of Cancer 986
National quality forum 439
National Standard Treatment Guidelines 941f
National Tobacco Control Programme 986
Natriuretic peptide 157, 397
B-type 76, 78, 216, 220, 239
Nausea 9
symptoms of 14
Nebivolol 657, 657f, 658f
induced vasodilation 658f
Neck veins 28
Nellix sac sealing device 552
principle of 553f
Neo-aortic area 44
Neointimal hyperplasia 503
Neonatal interventions 332
Neonatal mortality 836
Neoplasms 601
Nephropathy 799
anticoagulant related 799
Nephrotic syndrome 813
Neprilysin inhibitor 242
Neurocirculatory asthenia 10
Neurofibromatosis 20
Neurofibrosarcoma 909
Neurology 997
Neuromuscular
diseases 278, 745
disorders 233
Neuroprotection system 549
Neuropsychiatric disorders 473
New York Heart Association 109, 163, 191, 213, 231, 586, 601
classification 832
functional classifications 4t
Newer angiotensin receptor blocker 653
Newer beta-blocker 657
Newer calcium channel blocker 655
NexGen coronary stent system 498
Nicorandil 400, 434, 453
in angina, impact of 400
Nicotine 976
replacement therapy 976
Nifedipine 252, 833
Night sweats 623
Nitrates 399, 452
Nitric oxide 657, 661, 773
in salt homeostasis 661
Nitroglycerine 426
NOACs See Novel oral anticoagulants
Nocturnal dyspnea, causes of 8
Nodecline 977
Nodular adrenocortical disease 927
Nodules 24
Nonarrhythmic cardiac cause 10
Non-cardiac surgery 184
Noncaseating granuloma 263
Noncommunicable diseases 62, 77, 210, 771
Noncoronary cardiac surgery 891
Nonfamilial myxoma 920
Nonfatal myocardial infarction 397
Noninvasive cardiac imaging 895
Noninvasive stress testing 407t
Noninvasive testing 447
risk stratification by 406
Nonischemic cardiomyopathy 243, 740
Nonischemic dilated cardiomyopathy 766
Nonischemic pain 9
Nonmyxoma benign tumor 929, 931, 932
Non-myxomatous benign tumors, primary 929t
Nonosteogenic calcification 156
Nonpharmacological interventions 242
Non-ST elevation
acute coronary syndrome, management of 395
myocardial infarction 71, 397, 404f, 405t, 408b
myocardial infarction/unstable angina, epidemiology of 395
Nonsteroidal anti-inflammatory drugs 298, 819
Nonsustained ventricular tachycardia 253, 263, 719
multiple repetitive 248
Non-tender macular lesion 24
Non-viable myocardium 858f
Nonvitamin K oral anticoagulants 799, 800, 800t, 802, 802, 819f, 820t
pharmacokinetics of 802
Noonan's syndrome 20, 38, 258
Nordic-Baltic-British left main revascularization study 534
Norepinephrine 252
Normotension 653
Normothermic donor organ transport 604
Novel oral anticoagulants 403, 751, 796, 801, 807, 808
advent of 749
reversal agents of 824
Novolimus 491
N-terminal pro B-type natriuretic peptide 70, 76, 78, 216, 221
Nuclear cardiology 889
Nuclear data 892
Nucleotide polymorphism, single 389, 810
O
Obesity 221, 224, 369, 601, 651, 782, 953, 969, 982
abdominal 372, 466, 782, 783t
guidelines 787
Obliterative cardiomyopathies 273
Obstructing mitral valve 914f
Obstructive airways disease, chronic 6
Obstructive pulmonary disease, chronic 29, 38, 85f, 172, 221, 533, 540, 652
Obstructive sleep apnea 652
Obstructive symptoms 916
Occluded bypass grafts 561
Occlusive balloons 549
Off-pump techniques, surgeons practicing 583
Omega 3 FA 977
Oncology 997
On-pump versus off-pump 579
Opioids 400
Optical coherence tomography 507, 508f, 546
data 507f
Optimal medical therapy 455
Oral amiodarone 138
Oral anticoagulant 109, 796, 807810
action of 799f
bleeding management of 824
therapy 798t
Oral anticoagulation 594, 824b
therapy 796
Oral contraceptive 676
Oral dimethyl fumarate, safety of 997
Oral nitrate therapy 399
Oral penicillin 94
Oral salt-loading 680
Orbital atherectomy device 561
Organ care systems 604
Organic ejection systolic murmur 52
differentiation of 53t
Organic murmurs 52
Organic tricuspid valve 883
disease 99, 146
Orphan status 95
Orthopnea 8, 67, 130
Osler's maneuver 37
Osler's nodes 25
Osteoblastic transdifferentiation, markers of 157
Osteogenic signalling, direct inhibitors of 156
Osteopontin 157
Osteosarcoma 909
Ostial renal artery
bilateral 671f
stenosis, bilateral 668f
Ostial superficial femoral artery 558f
Outward systolic movement 42
Over wire technique 522f
Owl eye appearance 274f
Oxidative stress 956
Oxygen therapy, role of 181
P
PA See Pulmonary artery
Pacemaker 767
sounds 49
Paclitaxel 491
eluting stent 490, 494, 498, 507
Page's mosaic theory of hypertension 655f
Paget's disease 57
Pain
abdominal 18
amelioration of 398
Palliative care 215
Palmar xanthoma 24
Palpation 39
technique 39
Palpitation 10, 11
approach 11
drugs 11
etiology 10
symptoms 11
Pan African pulmonary hypertension cohort registry 172
Pancreatic beta cells 774
Pancreatic cancer 920
Panic disorder 10
Pansystolic murmur 69f
Papillary fibroelastoma 904, 905, 906f
attached 906f
gross specimen of 906f
Papillary mass in atrioventricular groove 909f
Papillary muscle 138
dysfunction 55, 56, 56t, 428
rupture 428
Paracetamol, use of 810
Paradoxical coronary embolism 389
Paradoxical split, types of 46t
Paralysis 815
Parenteral anticoagulation in acute DVT treatment 818b
Parenteral benzathine penicillin 131
Paroxysmal hypoxic spell 17
Paroxysmal nocturnal dyspnea 8, 129
Paroxysmal supraventricular tachycardia 63
Parvus et tardus 129
Patent ductus arteriosus 20, 21, 34, 39, 46, 50, 60, 65, 177, 178, 323, 325, 343
stenting of 345
Paul wood series 177t
PCSK9 inhibitors 689
Peak platelet inhibition 401t
Pectus excavatum 83f
Pediatric arrhythmias, drug therapy of 731
Pediatric cardiac electrophysiology 732
Pediatric Cardiac Society 732
Pediatric cardiology 353
Pediatric electrophysiology 729
resources for 731
Pediatric heart care, shortcomings in 352
Pediatric interventions 332
Pediatric tachycardias 727
Penile cavernosal arterial peak velocity 563
Pentoxifylline 846
Peptic ulcer 132
Percutaneous aortic valves, types of 526
Percutaneous balloon mitral
commissurotomy 752
valvuloplasty 514, 524
Percutaneous coronary intervention 390, 404, 405, 423, 455, 458, 469, 474, 489, 532, 533, 539, 577, 808, 809
failed 578
failure 537t
primary 766
with stent, development of 489
Percutaneous intervention 670t
Percutaneous mitral
commissurotomy 110
valvotomy 109
complications of 111
valvuloplasty 109
Percutaneous renal revascularization 666
Percutaneous transluminal
angioplasty 565
procedure 556f
balloon angioplasty 557, 561, 615, 668
coronary angioplasty 470
renal angioplasty 615, 668
Pericardial abscess 1003
Pericardial calcification 84f
Pericardial constriction 1003
Pericardial cyst 84, 301
Pericardial diseases 293
Pericardial effusion 299, 300, 429, 523, 907, 1005
culture of 1005
signs of 43t
Pericardial fluid 1005
Pericardial mesothelioma 910
Pericardial rub 49
Pericardial tamponade 299, 523
diagnosis 300
treatment 300
Pericardial tuberculosis 1002
Pericardial tumors 903
Pericardiectomy 297, 1006
Pericardiocentesis 287
Pericarditis 64
acute 10, 293, 294
causes of 10
clinical manifestations, acute 293
etiology, acute 293
treatment, acute 294
Peripartum cardiomyopathy 231, 233, 235, 842, 843, 845, 848
current definition 842
diagnosis of 845
epidemiology 842
management 846
pathophysiology of 843, 844f
risk factors 843
role of inflammation in 843
Peripheral arterial disease, management of 559t
Peripheral artery disease 546, 703, 751, 797
Peripheral cyanosis 26t
Peripheral fractional flow reserve 546
Peripheral pulmonary artery stenosis 54
Peripheral resistance 845
Peripheral vascular disease 25, 544, 945
epidemiology 546
history of 545
imaging 546
incidence of 773
Peripheral vascular
interventions 544, 547
resistance 834, 845
Peripheral venous contrast echo 855f
Peripheral vessels 33f
Periprocedural care 515
Permanent pacemaker implantation 253, 745
technique of 747
Persistent pulmonary hypertension 188
Peyronie's disease 563
Phaces syndrome 20
Pharmacologic treatment 681
Phenobarbitone 820
Phenytoin 820
Pheochromocytoma 232, 676
Phlebography 817
Phonocardiogram 30f
Phosphodiesterase-5 inhibitors 182, 195
Photodynamic therapy 561
Photoplethysmogram 954
Physical activity, promotion of 974
Physical exercises 951
Physiologic murmurs 51
Pig tail catheter 520f
Pistol shot sound 34, 67, 143
Pitres sign 43
Pitting edema 815
assessment of 27t
Plant protein 963
Plaque characteristics, evaluation of 891
Plasma
aldosterone concentration 680
levels of von Willebrand factor 773
protein binding 820
renin activity 680
Plasminogen 702
activator inhibitor 785, 969
Platelet
size and function 371
volume, mean 371
Platinum cobalt chromium 508
Platypnea 8
Pleomorphic sarcoma 909, 909f
Pleomorphic ventricular tachycardia 264f
Pleuritic chest pain 8
Pneumonia 945
Policymakers 985
Polyethylene tube 518
Polymer 492
Polymerase chain reaction 263, 1005
Polymorphic ventricular tachycardia 753
Polymorphonuclear leukocytosis 1002
Polypill strategy 384
Polytetrafluoroethylene 552
Polyunsaturated fatty acid 775, 961, 977
Pompey's syndrome 258
Poor/depleting infrastructure 938
Popliteal blood pressure 68
Popliteal stenosis, single 560
Porcine heterograft 594
Posaconazole 820
Post-balloon
angiogram 338f
dilatation 530
Postcardiac intervention 740
Postcardiac surgery 740
Post-endovenous laser therapy 564f
Post-EVAR using nellix device 553f
Postinfarct ventricular septal defect 585
Postirradiation syndromes 278
Postmenopausal hormonal therapy 194
Postmyocardial infarction syndrome 431
Postprandial blood glucose 954
Postradiation therapy 740
Post-streptococcal glomerulonephritis 94
Potain's sign 43
Potential nonlegal issues 884
PPBG See Postprandial blood glucose
PPG See Photoplethysmogram
Pranayama 951, 975
Prasugrel 401
Pre-conception and Pre-natal Diagnostic Techniques Act 885
Precordium 130
Prednisone 629
Preeclampsia 848
Pre-endovenous laser therapy 564f
Preexcitation syndrome 712
Preformed panel reactive antibodies 601
Pregnancy 148, 184, 194, 255
Prehypertension 652
Pressure difference, abnormalities in 38t
Pressure half time 104, 876
Primary aldosteronism, subtypes of 679, 679t
Primigravida 836, 843, 848
Printzmetal angina 9
Private-public-partnership 653
PRKAR1A gene 920
Profile sign 26
Progesterone only pills 184
Progressive adipocyte enlargement 784
Prolactin levels in peripartum cardiomyopathy, role of 843
Prolactinoma 920
Promethazine 727
Prominent diastolic flow 275f
Prominent neovascularization 125
Propafenone 731
Prophylactic antibiotics 833
Prophylaxis 167
Propranolol 730f
Prostacyclin 196
analogs 182, 196
receptor agonists 196
Prosthesis 526
choice of 166
selection 592t
Prosthetic heart valve 58f, 591, 836
designs, types of 594
murmurs 57
Prosthetic mitral valve 84f
Prosthetic valve 591, 597, 796, 833, 834
abnormal 58t
choice of 591
endocarditis 163165
blood culture 164
clinical presentation 164
diagnosis 164
echocardiography 164
management 165
postoperative complications 166
prognosis 167
surgery 166
intervention of 593t
normal 58t
replacement 165, 591
sounds 49
abnormal 50t
normal 50t
type of 163
Protein deficiency 232
Prothrombin
complex concentrates 804, 805
time 803
Proximal cap blunt 537
Proximal epicardial artery 424
Pseudo-aneurysms 429
Pseudo-ejection sounds 49
Pseudohypertension 37
Pseudoxanthoma elasticum 278
Psychosocial risk factors 983
Psychosocial stress 372, 955
Public Health Foundation 987
Public health
role of 362
sector 937
Public private partnership 658
Pudendal artery
internal 562
stenosis 562, 564f
internal 562, 563f
Pulmonary angiography 817
Pulmonary apoplexy 99
Pulmonary arterial hypertension 32, 55, 82fc, 102, 171, 172, 176, 187, 188, 188b, 1191f193f, 194, 195, 195t, 196
associated 188
pathogenesis of 190f
severe 99
signs of 191f
symptoms of 191f
Pulmonary arterial pressure
diastolic 192
mean 187, 192
systolic 192
Pulmonary artery 50, 55, 84f, 187, 193, 349, 915, 929
bifurcation 855f
dissection 183
hypertension 65, 832
diagnosis of 191
involvement 618f
lesion 610
main 101
pressure 76, 834, 836
smooth muscle cells 188
systolic pressure 99, 109, 137, 188, 193t, 515
wedge pressure 240, 515
Pulmonary atresia 20, 328
Pulmonary capillary wedge pressure 65, 76, 106, 171, 192, 519f, 831
Pulmonary disease 188
Pulmonary dyspnea 7
Pulmonary embolism 6, 82, 565, 795, 813, 917
rule-out criteria 81b
severity index 814
treatment of 798
Pulmonary flow, large 16
Pulmonary hypertension 76, 81, 171, 172, 187, 193, 193t, 194, 210, 224, 515, 634
assessment of 105
chronic 100
clinical classification of 188, 188b
Danapoint classification of 171t
prevalence of 172t
primary 25, 146, 180
types of 189f
Pulmonary infarction 99
Pulmonary overcirculation 16
Pulmonary regurgitation 50, 60
Pulmonary stenosis 20, 34, 50, 54, 54t, 60
Pulmonary thromboembolism 171
Pulmonary thrombus 183
Pulmonary valve 916
dilatation 334
complication 335
success of procedure 335
Pulmonary vascular
disease 171
resistance 176, 187, 353, 600
Pulmonary vein
cephalization of 85f, 136f
dilation 340
isolation, surgical 729f
right upper 342f
technique, left upper 342f
Pulmonary venous hypertension 102
Pulmonary venous pressure 100
Pulmonic stenosis 20, 146
critical 335
Pulsatile uvula 67
Pulsations, abnormalities in 39t
Pulse
bisferiens 130
causes of irregular 33t
double-peaked 35
examination of 33
pressure, abnormalities in 38t
wave velocity 774
Pulseless disease 621
Pulsus alternans 34, 68
Pulsus bigeminy 33
Pulsus bisferiens 35, 68
Pulsus paradoxus 33, 36
reversed 36
Pulsus parvus 36
Pure mitral stenosis 874
Pyogenic infection 299
Q
QRS
axis 101
complex tachycardias
narrow 716
wide 717
escape rhythm 430, 740
morphology 767
Qualitative studies 991
Quality control documentation 735
Quality council 439
Quality Improvement Program 441, 736, 994
Quantitative coronary angiography 503, 977
Quantitative intravascular ultrasound 503
Quincke's pulse 130
Quincke's sign 67, 144
Quinidine 731, 802, 820
R
RA See Right atrium
Radial artery 578, 583
Radiofrequency ablation 255, 753
catheter 730f
number of 729f
techniques of 749
Radiofrequency catheter ablation 723725, 733, 734f
of accessory pathways 725
of ventricular tachycardia 726
Radiology in mitral stenosis 101
Radio-opacity 497
Raised lactic dehydrogenase 1005
Randomized control trials 195, 508, 534t, 953
Ranolazine 400, 453, 454
Rapid filling wave 41
Rapid late diastolic filling 48
Rashtriya Bal Swasthya Karyakram 317
Rashtriya Kishor Swasthya Karyakram 776
Rate control strategy 752
Rate versus rhythm control 752
Reactive airway disease 399
Recoil and radial strength 495
Recombinant tissue plasminogen activator 807
Recurrent cardiovascular 480
Redundant myxomatous valve 138f
Regulatory issues 948
Regurgitant lesions 10, 832
Regurgitant systolic murmurs 55
Reid scoring system 105
Reinfarction 426
Release-T PES 498
Relisys medical devices 499
Renal abdominal aortic aneurysm repair 556
Renal angioplasty 555
Renal arterial involvement, bilateral 619f
Renal artery 557, 672f
lesions 667
right 671f
stenosis 555, 612, 670t
bilateral 557f
non-atherosclerotic 669
stenting 554
Renal atherosclerotic lesion 555, 667
Renal cell carcinoma 57
Renal damage 706
Renal disease 221
development of end-stage 556
primary 676
Renal dysfunction 600
progression of 555
Renal elimination 820
Renal failure 563, 740, 669f
acute 117
after angiography 669f
Renal function, abnormal 797
Renal insufficiency 822
Renal revascularization 666, 667
Renal salvage 556
Renal transplantation 797
Renal vein, selective 678
Renin inhibitors, direct 653
Renin-angiotensin aldosterone system 653, 661
blockers 403, 451
inhibitors of 450
role of 661
Renin-angiotensin inhibition 706
Renin-angiotensin system 678
Renovascular hypertension 665, 673, 677
clinical clues 677
diagnosis of 677b
in adults 665
pathophysiology 677
prevalence 677
primary diagnostic tests 677
treatment 678
unusual causes of 673
Repeat revascularization 390
Reperfusion therapy 425
choice of 419
Repolarization syndrome 413
Residual atrial septal defect 524
Residual risk 705
Respiratory
diseases 172
infections 99
signs 623
symptoms 623
Restrictive cardiac disorders 278b
Restrictive cardiomyopathy 192f, 273, 274f, 277, 288
clinical pattern of 276f
treatment of 287
Restrictive filling 277
Revascularisation 454
indications for 577
procedures, emergency repeat 417
Reversal agents, specific 803, 805t
Revised National Tuberculosis Control Programme 1002
Reye's syndrome 132
Reynolds risk score 703
Rhabdomyoma 903, 907, 908, 926
multiple 908f
Rhabdomyosarcoma 904, 909, 910, 932
RHD See Rheumatic heart disease
Rheumatic aortic
insufficiency 129
regurgitation 129
stenosis 128
valve disease 125, 127, 876
epidemiology of 126
surgical treatment of 132
Rheumatic arthritis, treatment of 132
Rheumatic atrial
fibrillation 729
treatment of 729
trial 749
Rheumatic carditis 729
Rheumatic disease 611
Rheumatic endocarditis 125
Rheumatic fever 15, 90, 91, 92t, 95, 98, 134
acute 116, 125, 127, 135, 874
prevalence of 514, 591
prophylaxis 108
Rheumatic heart disease 75, 77, 89, 90, 92t, 95, 98, 125, 126, 134, 147, 153, 155, 172, 203, 209, 211, 215, 220, 571, 729, 874, 883, 893
chronic 115
in pregnancy 147, 831
multivalvular involvement in 876
primary prevention 131
registry 837
secondary prevention 131
treatment of 131
Rheumatic mitral
regurgitation 115, 883
chronic 115, 119
stenosis 98, 113
valve
disease 874
involvement 875f
Rheumatic origin 128
multivalvular heart disease of 134
Rheumatic stenotic aortic valve disease 129
Rheumatic valvular heart disease 148, 172, 749, 751, 753fc, 796
Rheumatogenic strains 96
Rheumatoid arthritis 232, 970
Rhinitis 132
Rhythm control drugs 753
Rifampicin 810, 820
Right heart failure, severe 99
Right internal mammary artery 584, 584f
Right ventricle 278, 282, 286, 879, 915, 916, 919, 929, 930
Right ventricular 46, 60
angiogram 281f, 282f
end-diastolic pressure 240
endomyocardial fibrosis 281f, 282f
failure 65
severe 428
hypertrophy 65
involvement 248
myocardial infarction 146
outflow tract 17, 50, 282, 854
dilatation 281f
obstruction 327
pressure 876
RIMA See Right internal mammary artery
Ritscher-Schinzel syndrome 20
Rivaroxaban 751, 801, 804, 805, 819, 821
Road map moving forward 483t
Robotic coronary artery bypass grafting surgery 584
Rosenbachsign 130
Rosuvastatin 706
affecting aortic valve endothelium 157
Rotch's sign 43
Rubinstein-Taybi syndrome 20
Rupture sinus of valsalva 50, 57
aneurysm 327
RV See Right ventricle
S
Salt homeostasis 661
Salt intake 661, 662t
physiological effects of 660
Same day access clinics, role of 225
Sansom's sign 43
Saphenous vein 580
grafts 582
long 582f, 583f
Sarcoidosis 241, 262, 277, 278, 285
malignant tumors 740
Sarcoma 909
Sarcomere mutations, multiple 248
Saxagliptin 994
SBP See Systolic blood pressure
Schamroth's window test 26
Schistosomiasis 171, 188
Sclerodegenerative AV block 740
Scleroderma 232, 278
Scoring balloons 561
Scrub typhus 879
Sedentary lifestyle 774
Seizure 14t
Selenium 963
Selexipag 196
Septal dilatation 520f
Septal myectomy, surgical 252, 259
Septal puncture 517, 518f
steps of 517t
Septal reduction therapy 251, 252, 253
Septic vegetations 389
Serum
creatinine 797, 803
ferritin 893
fibrinogen 972
homocysteine 972
Sexual function, regulation of 785
Shear stress, complex 155
Shock 9
cardiogenic 214, 422, 424, 428, 578
Short conical duct 344f
Short term parenteral inotropic agents 242
Sick sinus syndrome 79
Sildenafil 182, 195
Silent killer 651
Simpson's formula 876
Simpson-Golabi-Behmel syndrome 20
Simultaneous pressure tracing 100f
Simvastatin, combination of 689
Single vessel disease 466
Single-balloon technique 110, 111
Sinus
arrhythmia 33
bradyarrhythmias 715
bradycardia 32, 399, 430
cycle length 715
node dysfunction 65
prevalence of 739
node function 714
node recovery time 714
rhythm 753
normal 572, 712f
tachycardia 67
inappropriate 33
Sirolimus 510
eluting biodegradable polymer-coated stent 501
eluting stents 490, 494, 498
Sitagliptin 994
Six-minute walking test 5, 82, 191
Skeletonized internal mammary artery 582, 582f
Skin
in cardiology, examination of 23t
lesions 38, 39, 927
myxomas 927
necrosis 799
Sleep 982
apnea syndrome 676
disorderd breathing 188
Smith-Lemli-Opitz syndrome 20
Smoke, second hand 975
Smoke-free legislation 975
Smokeless tobacco, usage of 976
Smoking 229, 370, 955
Smoking/tobacco 479
Smooth muscle cell 189, 656f
Society of Thoracic Surgeons 456
guidelines 578
Socioeconomic environment 940
Socioeconomic status 412
Sodium channel mutations 238
Soft plaque 973
Solitary functioning kidney 669f
Special economic zone 352
Specific activity scales 4t
Speckle tracking 859
echocardiography 859
Spider cell in rhabdomyoma 908f
Spinal anesthesia 838
Spiritual discipline 951
Spironolactone 428, 434, 682
Spontaneous coronary dissection 389
Spontaneous echo 751
Spontaneous recovery 847
Square root sign 31
ST elevation myocardial infarction 74f, 413, 413b, 414b, 415, 423, 425, 440, 760
acute 411
complications of 427
diagnosis of 412
epidemiology of 411
infarction 72, 73f, 213
ischemic complications of 431
management of 411, 419, 420, 424
treatment of 418t
Stable chronic heart failure 478
Stable coronary artery disease 445
clinical features 446
epidemiology 445
etiopathology 446
evaluation 446
lifestyle modification 449
management of protocols of 943f
medical treatment 450
risk factor modification 449
treatment of 448
Stable governance 946
Stable hypertension 676
Stainless steel alloy 491
Stakeholder fragmentation 442
Standard treatment guidelines 939
categories of 941
development of 939
Staphylococcus epidermidis 164
Starling's equation 65
Starling's mechanism 230
Starr-Edwards prosthesis 573
Statin 986
and nonstatins, use of 698
Stearic acids 977
Stem cell
therapy 350f
transplantation 287
Stenosis 557
like congenital mitral stenosis 98
mild 104f
multiple 560
of infrarenal aorta 559
severity of 141
Stenosis/bifurcations, left main 540
Stenotic lesions predominate 623
Stent 557, 561, 565
choice of 405
design 496
frame 527
implantation 752
material 492
platform 492
self-expanding 550, 561
thrombosis 535
underexpansion/restenosis 540
Stentless bioprostheses 166
Steroids, dose of 603
Stethoscope 43
Still's disease 622
Still's murmur 51
Stopping smoking 975
Storage diseases 278
Strawberry 963
Streptococcus viridans 163, 164
Stress
causing cardiovascular disease 952f
echocardiography 251, 467
induced cardiomyopathy 879
management of 449
nuclear study 893
testing 250, 887
in mitral stenosis 107
thallium scintigraphy 468
Stretching 951
String sign 548
Stroke 529, 797, 945, 967, 986
embolism 524
high risk of 548
prevention
in atrial fibrillation 751
secondary 806, 806t
therapy 796
with atrial fibrillation 801t
procedural 529
Stromal preadipocytes 784
Strut thickness 492
Subaortic stenosis 326
Subclavian artery 557
blood flow, absence of 678f
left 555f
occlusion, bilateral 678f
Subclavian vein 565
Subclinical carditis 121
Subcutaneous nodule 25
Subintimal angioplasty 561
Subintimal entry of device 562f
Sublingual nitroglycerin dose 416
Submaximal exercise test 6
Submitting to painful tests 948
Subsequent pregnancy 847
Subvalvular
disease, severe 521
fibrosis 516
stenosis, severe 519, 521
Sub-xiphoid impulse 42
Sudden cardiac death 246, 262, 756, 757t, 758, 761f, 766
prevention 762
profile of 756
risk stratification 253
Sudden death 907
myocardial infarction 758
risk factors for 248
Sulfhemoglobin 21
Summation gallop 48
Superoxide 661
Supportive therapy 194
Supracardiac shadow, widening of 85f
Supraflex 500
SES 498, 505
Supralimus 501
SES 498
Supralimus-core
combines 501
SES 498, 505
stent 501, 507
Supralimus-eluting stents 499
Suprasystolic pressure 37
Supravalvar tethering 335f
Supravalvular aortic stenosis 326
Supraventricular tachycardia 25, 718
management of 712
Surgical versus percutaneous techniques 112
Surveillance endomyocardial biopsies 604
Suzman's sign 39
Sydenham chorea 15
Sympathetic nervous system 657
Symptomatic bradycardia 745
Syncope 11, 13, 14t, 78, 916
causes of 13t
exertional 247f
higher risk 13
occurring 13
unexplained 720
Synovial sarcoma 909
Syntax scores 534
Syntax trial 458
Systemic artery to right heart 57
Systemic congestion 916
Systemic disorders 188
Systemic embolism, prevention of 798
Systemic embolization 916
Systemic hypertension 258
Systemic illness 6
Systemic inflammation 773
Systemic lupus erythematosus 25, 98, 232, 389
Systemic manifestations 268
cough 268
fever 268
joint pain 268
weight loss 268
Systemic recurrent emboli 798
Systemic systolic hypertension 145
Systemic vein stenosis, dilation of 340
Systolic anterior motion 854f
Systolic blood pressure 204, 662, 783, 797, 953
intervention trial 449
Systolic click, late 47
Systolic closure, mid 854f
Systolic dysfunction 64, 188, 259
Systolic heart failure 877
Systolic murmur change with bedside maneuvers 53t
Systolic pressure, elevated 144
Systolic retraction, mid 41
Systolic thrill felt 143
T
TA See Takayasu arteritis
Tachyarrhythmias 13, 325, 716
supraventricular 67
Tachycardia 67, 399
bradycardia syndrome 79
induced cardiomyopathy 231, 237
unresponsive 730f
Tachycardiomyopathy 238
Tachypnea 16
Tachypneic baby 16
Tackle hypertriglyceridemia 698
Tacrolimus 820
Tadalafil 182, 195
Tafazzin related gene mutation causes 242
Takayasu's arteritis 36, 238, 553, 555f, 557t, 609, 613, 615, 617b, 621, 624, 624t, 625, 626t, 627, 633t, 634t, 635, 666, 669, 670, 671f, 672, 673, 678, 678f
childhood 628t
clinical features 612
computed tomography 613
diagnosis of 610t, 625
etiopathogenesis of 611
history 609
imaging in 613
Ishikawa's diagnostic criteria for 626t, 627t
magnetic resonance imaging 613
management 614
of chronic phase of 615
nonspecific 617
prognosis 616
signs of 623b
surgery for 633t
surgical management 615
symptoms of 623b
ultrasound 613
Takayasu's disease 68, 609
classification of 624t
Takayasu's syndrome 678
Takotsubo cardiomyopathy 231, 237
Takotsubo syndrome 879
Tamponade 429, 838, 1003
acute 300
Target lesion revascularization 497, 506
Target therapeutic range 751
Target vessel myocardial infarction 506
Target vessel revascularization 506
Taussig bing anomaly 26
Taxus stent 508
Temporary mechanical circulatory support 242
Tendinous xanthoma 24
Teneligliptin therapy 779
Teratogenic 837
Teratogenicity during pregnancy 799
Teratoma 904, 926
Terminating tachycardia 731f
Tetralogy of Fallot 8, 20, 54, 60, 323, 328, 345
differential diagnosis of 54t
repair 574
Tetrilimus 502
EES 498, 506
Thallium-201 424
T-helper cells 234
Therapeutic range 801
time in 819
Therapeutic strategy 158
for degenerative heart disease 157
Thiamine deficiency 232
Thinking techniques 951
Thoracic aorta 551f, 557
lesion, descending 610
Thoracic aortic aneurysm 550
Thoracic endovascular aortic repair 550
Thoracoabdomen computed tomography 555f
Thoracoabdominal aorta 556f
ballooning 556f
Thoracoabdominal aortic aneurysm 551f
Thoracotomy, anterior 584f
Three-dimensional echocardiography 105, 858
Three-dimensional reconstruction 75f
Thrifty phenotype 775
Thrombin 803
inhibitor, direct 819
time 803
Thrombocytopenia 916
Thromboembolic pulmonary hypertension, chronic 188, 817
Thromboembolism 561
prevention of 108
Thrombogenic, risk factors 370, 371
Thromboglobulin 796
Thrombolysis 390, 412, 416, 417
and interventional therapy 390
in myocardial infarction 398
in venous thromboembolism 823
time to 441
Thrombolytic 419
agents 418t
Thrombophilia, acquired 813
Thrombosed dialysis access grafts 561
Thrombosed popliteal aneurysm 561
Thrombosis 189, 773
Thrombus 548
aspiration 405, 423
Thyroglobulin 955
Thyroid
disease 229
function tests 239
Thyrotoxicosis 8, 622
Ticagrelor 401
Tissue
biopsy 267
Doppler imaging 859
heart valve 798
hypoxia 673
plasminogen activator 417
Tobacco 975
consumption 651
use 775
Tocolytic use 843
Torsades de pointes 80, 722
causes of 80b
Tortuosity present 537
Total anomalous pulmonary venous connection 20, 25
Total arterial revascularization 583
Total cholesterol 378f, 968
levels of 360
Total leukocyte count 82
Total myxoma 919
Total occlusion, chronic 506, 532, 537, 537t, 540, 560
Total paradox 36
Trackability 497
Tranexamic acid 805
Tranquillizers 10
Transatrial repair of double-outlet right ventricle 350
Transcatheter
aortic valve implantation 514, 525, 526
complications 529
future of 530
patient selection 528
procedure 528
aortic valve replacement 76, 142
closure of intracardiac shunts 340
procedures 861
replacement of pulmonary valve 345
techniques 574
Transcendental meditation 952
Transesophageal echocardiogram 82
Transesophageal echocardiography 72, 105, 109, 116, 122, 905
left atrium appendage clot 104f
role of 165
Trans-fatty acids 775
Transient ischemic attack 548, 797, 807, 807f, 835
Translumina therapeutics 502
Transmyocardial laser revascularization 585
Transmyocardial revascularization 585
Transplant rejection 233
Transpulmonary gradient 600
Transseptal approach via right atrium 928f
Transseptal puncture 517
Transthoracic
and transesophageal echocardiography 878f
echocardiogram 927f
echocardiography 7375, 109, 134, 165, 247, 429, 524f, 875f
Transthyretin protein 287
Transthyretin, wild type of 287
Trash foot 561
Traube's sign 67, 130, 143
Traube's space 43
Treadmill test 109
positive 892
Trepopnea 8
Treprostinil 196
Trials with intensive statin therapy 690t
Tricuspid atresia 25
Tricuspid regurgitation 50, 56t, 60, 100, 136, 146, 154, 874, 876, 918
severe 31
velocity 188, 193, 193t
Tricuspid stenosis 50, 60, 136, 146, 147, 154, 918
presystolic murmur of 69f
Tricuspid valve 711
disease 876, 918
surgical management of 147
Triglyceride 369, 778, 845
levels 367
high 434, 691, 782
rich LDL particles 774
significance of 698
Trimetazidine 434, 454
Triple vessel disease 445, 457, 458
Trivandrum heart failure registry 203, 209, 994
Tropical endomyocardial fibrosis 273, 877
Tropomyocin 127
Troponin 233, 233t, 395
testing 414
Truncus arteriosus 20, 177
TS See Tricuspid stenosis
TTK Chitra valve 108f, 109
Tubercular constrictive pericarditis, complications of 1003
Tubercular myocarditis 1003
Tubercular pericardial effusion 1002, 1006t
diagnosis of 1005
Tubercular pericarditis 876, 1006t
Tuberculin skin test 263, 267, 1004
Tuberculoma type 1003
Tuberculosis 183, 262, 348, 612, 1002, 1006
bacillus 622
diagnostic evaluation 1003
pathophysiology 1002
prevalence of 296
Tuberculous
aortitis 622
pericardial effusion 1004b
pericarditis 1002
sarcoidosis 262, 263
Tuberous sclerosis 929
Tuberous xanthoma 24
Tumor
acquired 904
attachment of 919
benign 902, 903, 905
fibroelastoma 902
fibroma 902
hemangioma 902
lipoma 902
lipomatous hypertrophy 902
myxoma 902, 905
papillary fibroelastoma 905
rhabdomyoma 902
congenital 903
fibroma 901
hemangioma 901
histological classification of 903t
lipomatous hypertrophy 901
malignant 902904
angiosarcoma 902
fibrosarcoma 902
liposarcoma 902
lymphoma 902
mesothelioma 902
rhabdomyosarcoma 902
undifferentiated sarcoma 902
mass 855
multiplicity of 919
myxoma 901
necrosis
factor 70
factor alpha 785, 843
of heart, primary 926
of soft tissue and bone, classification of 903t
papillary fibroelastoma 901
paraganglioma 901
primary
lymphoma 901
malignant 930, 930t, 932
rhabdomyoma 901
rhabdomyosarcoma 901
sarcoma 901
Turner syndrome 38
Twin pregnancy 843
Two-dimensional echocardiography 103, 118, 267f, 854
Two-dimensional transthoracic examination 247f
U
Ulcerative colitis 951
ULMS See Unprotected left main stem
Ultrasound Practice Law 885
Ultrasound scan, abdominal 191
Unfractionated heparin 402, 423, 833
United States food and drug administration 489
United States vital statistics 756
Unprotected left main
disease 457, 459
stem 532
Unstable angina 9, 395, 397, 399, 404f, 405t, 408b, 556
Upper limb
signs 623
symptoms 623
Upper lobe vessels 101
Urate metabolism 18
Uterine blood flow 845
V
Vaginal delivery 837
Valve
area 103
bank 574
calcification 99
design 530
deterioration, structural 595
disease 751
morphology 103, 833
prosthesis, decision of 592
regurgitation 121
stenosis and regurgitations 883
Valvular aortic stenosis 326
Valvular calcification 516, 519
Valvular heart disease 87, 172, 540, 572, 798
causes of 115
Valvular interventions 514
Valvular myxoma 920
Valvular pathologies, types of 835
Valvulitis 131
Valvuloplasty 519f
Vardenafil 182, 195
Varicose veins 563, 813
Vascular access 405, 517
Vascular age, concept of 970
Vascular calcification 799
Vascular complications 530
Vascular disease 13, 797
Vascular endothelial growth factor inhibitors 233
Vascular growth, impaired modulation of 773
Vascular injury 976
Vascular psychiatry 587
Vascular remodelling, dysregulation of 773
Vascular surgery 347
Vasculohormonal hypothesis 844f
Vasectomy 184
Vasoconstriction 189
Vasodilators 242
Vasopressin antagonism 207
Vasoreactivity testing 192
Vasospastic angina 413
Vein 36
harvesting technique, open 582
Vena cava
inferior 298, 521, 681
left superior 730f
superior 28, 29, 517, 565, 904
Vena contracta 118
Venous corrigan 30
Venous duplex scan 816
Venous interventions 563
Venous leak 563
Venous pressure in lower limbs 845
Venous thromboembolic disease, chronic 427
Venous thromboembolism 795, 796, 800t, 812, 824
acute 796
classification of 813
conventional treatment of 817
diagnosis of 814
invasive imaging modalities 817
pathophysiology 812
risk factors 812, 813b
treatment of 817
Venous thrombosis
prophylaxis of 798
treatment of 798
Ventilation 82
Ventricular aneurysm 266
formation 429
Ventricular arrhythmia 129, 216, 233, 262, 268, 430, 722, 740, 745
Ventricular assist device 600
Ventricular asystole 431
Ventricular complexes, premature 719
Ventricular contraction, premature 59, 263, 744f
Ventricular dilatation 64
Ventricular fibrillation 765
Ventricular myxoma 920
Ventricular pacing 746
Ventricular premature contraction 32
Ventricular rate 753
control of atrial tachyarrhythmias 723
Ventricular septal
defect 20, 31, 50, 56t, 60, 68, 74, 176178, 325, 328, 341, 348, 573
motion, abnormal 297
rupture 429, 467
Ventricular tachyarrhythmias 67, 266
Ventricular tachycardia 32, 64, 264f, 265f, 716, 723f, 765
Ventriculophasic sinus arrhythmia 742f
Verapamil 252, 452, 712, 802, 820
therapy 251
Verbal autopsy 758
Vertebral artery 557
Very low density lipoprotein 687, 954
Vessel disease, multiple 386
Vibrating neck 11
Vienna prediction model 821t
Vijaya's echo criteria 123
Viral hemorrhagic disease 750
Viral myocarditis 233
Virchow's triad 812f
Visceral pericardium 293
Visual analog scale of dyspnea 7f
Visual signs 623
Visual symptoms 623
Vitamin 963
B6, deficiency of 972
C 963
D deficiency 969
K antagonist 751, 796, 798, 808, 819, 824
limitation of 798t
VLDL See Very low density lipoprotein
Voluntary health agencies 937
Vomiting 9
von Recklinghausen's disease 23
von Willebrand factor 805
Voriconazole 820
Vulvar disease 188
W
Waist circumference 21, 21t, 782, 783t
elevated 783
measurement of 783, 783f
Warfarin 796, 798, 805
Water hammer 143
pulse, causes of 34t
Weight gain 12, 785
Weight loss 623
Weight management 479
Weight reduction 786
Weighted chronic total occlusions score 537
Wenckebach phenomenon, electrocardiograph displays classical 741f
Whipple's disease 146
White edema 27
Wholesome wheat 979
Wide complex tachycardias 717
Wilkins score 105, 105t, 516t
Williams syndrome 20
Winter bronchitis 12, 99
Wire technique, modified over 522f
Wolff-Parkinson-White syndrome 46, 712, 718
Wood pecking sign 519
World Health Federation 839
World Health Organization 178, 193, 377, 771, 783f, 941, 1002
Worsens block 741
X
Xenograft 594
Xience prime EES 507
Xience stent 460
Xience V stents 503
Y
Yoga
and risk factors 952
in cardiovascular disease 951, 954f
role of 952, 953f
in diabetes mellitus, effect of 954t
in heart disease 956
in metabolic syndrome and obesity, effect of 955t
on hypertension, effect of 953t
on lipids, effect of 955t
studies, limitation of 957
Yolk sac tumor 904
Young hypertensives 652
Yukon choice
flex stent 502
stent 502
Z
Zotarolimus 491
DES 563
eluting stent 490, 507
×
Chapter Notes

Save Clear


1Clinical Cardiology: The Art that Still Survives in India

3Approach to a Cardiac Patient: Start with Meticulous History TakingCHAPTER 1

Arup Dasbiswas
 
INTRODUCTION
History taking is a scientific art of data collection. Appropriate history taking is not only the art of data collection; it is a technique of establishing contact at a personal level and touching the emotions and problems (beyond medical) of the patient. It is one of the greatest means of establishing interpersonal relationship. Therefore, elicitation of the history should be done by the cardiologist himself. Patient's behavior and body language should be noted while elaborating the history.
This also helps in selecting appropriate investigational techniques and collating the data collected from them. Investigations supplement but do not supplant appropriate clinical examination (which includes eliciting the history and conducting a physical examination). The history is the richest source of information regarding the patient's illness.1 Proper history taking establishes a bond between the patient and the physician.2 In our country, history taking has some special problems. This is due to difference in culture, religion, language, literacy status, etc. from region to region, state to state, and even district to district. The doctor has to have special patience when eliciting history from a patient who has linguistic barrier, low intelligence, premonition and fixed ideas about a disease, etc.
Documenting the history in a patient suffering from cardiovascular disease is basically the same as in case of Internal Medicine with some special emphasis on same cardinal symptoms of cardiac patients. This also requires differentiating the features that may arise from any other system (e.g., dyspnea of cardiac and respiratory system).
 
FUNCTIONAL CLASS
One important aspect of cardiac history taking is placing the patient in a particular functional class (keeping in mind the limitations and fallacies) (Table 1). This helps in present assessment and future follow up about the progress (natural course and effect of treatment). There are several methodologies, a few of which will be discussed in short.
 
Canadian Cardiovascular Society Functional Classification of Angina Pectoris5
This classification is based on the functional class in relation to angina only (Table 2).
 
Specific Activity Scale6
Specific activity scale denotes the activity in relation to usual daily life (Table 3).
 
Class I Activities
  • Carry at least 24 pounds up to eight steps: 10 METS
  • Carry objects that are at least 80 pounds: 8 METS4
    TABLE 1   New York Heart Association Functional Classifications3,4
    Functional capacity
    Objective assessment
    Class I
    Patie nts with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue. Palpitation dyspnea, or angina pain
    No objective evidence of cardiovascular disease
    Class II
    Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina pain
    Objective evidence of minimal cardiovascular disease
    Class III
    Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or angina pain
    Objective evidence of moderately severe cardiovascular disease
    Class IV
    Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the angina syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased
    Objective evidence of severe cardiovascular disease
    TABLE 2   Functional Class at Angina5
    Class I
    Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation
    Class II
    Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking Uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress or only during the few hours after awakening walking more than two blocks on the level and climbing more than one flight of stairs at a normal pace and in normal condition
    Class III
    Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one flight of stairs in normal condition and at normal pace
    Class IV
    Inability to carry on any physical activity without discomfort; anginal syndrome may be at rest
    TABLE 3   Specific Activity Scales6
    Class I
    Patient can perform to complete and activity requiring >7 metabolic equivalent (MET)
    Class II
    Patient can perform to complete any activity requiring >5 METS but cannot perform to complete activity requiring >7 METS
    Class III
    Patient can perform to complete any activity requiring >2 METS but cannot perform to complete activity requiring >5 METS
    Class IV
    Patient cannot perform to complete any activity requiring >2 METS
  • Do outdoor work (shovel snow, spade soil): 7 METS
  • Do recreational activities like skiing, basketball, touch football, squash handball, etc.: 7–10 METS
  • Jog or walk 5 miles an hour: 9 METS.
 
Class II Activities
  • Carry anything up a flight of eight steps without stopping: 5.0–5.5 METS
  • Have sexual intercourse without stopping: 5–5.5 METS
  • Garden rake weed: 5–6 METS
  • Walk at a 4-mile per hour rate on level ground: 5–6 METS.
 
Class III Activities
  • Walk down a flight of steps without stopping: 4.5–5.2 METS
  • Shower without stopping: 3.6–4.2 METS
  • Strip and make bed: 3.9–5 METS.
 
The Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale7
The Canadian Cardiovascular Society (CCS) Severity of Atrial Fibrillation (SAF) Scale is similar to the CCS Angina Functional Class. The CCS-SAF score is calculated using three steps:5
  • Symptoms (S): To assess the symptoms
  • Association (A): To decide the association of symptoms with atrial fibrillation
  • Functionality (F): To assess the functional status and quality of life of the patient due to the association (Boxes 1, 2 and Table 4).
 
Six-minute Walking Test9
This is a reliable, inexpensive, and simple objective test to assess functional capacity in patients with moderate to severe heart failure (HF). Various test protocols, like 2-minute, 6-minute, and 12-minute walking tests have been used. The 6-minute test was first standardized by Lipkin and associates.
  • The test is carried out in a level enclosed corridor 20 m long
  • Each patient is instructed to cover as much ground as possible in 6 minutes
  • Patient is told to walk continuously, if possible but that they could slow down or stop, if necessary
  • The aim is that at the end of the test, the patients believe that they could not have walked any further in the 6 minutes
  • The test may be repeated twice on the same day with at least 3–4 hours between tests.
TABLE 4   Duke Activity Status Index8
Activity
Weight
Degree of difficulty in the past 2 weeks for
1.
Walking indoor
1
2.
Walking a block or two
1
3.
Climbing a flight of stair
1
4.
Running a short distance
1
5.
Doing light housework
1.5
6.
Doing moderate housework
1.5
7.
Doing heavy housework
1.5
8.
Doing moderate to vigorous exercise
2.5
A final score was calculated by the summary of giving each item a value of 3 = done without difficulty, 2 = done with difficulty, and 1 = not done because of health reason. If any activity from 1 to 4 was not done because of health reason, it was skipped to activity 5.
6
This test may be less discriminating than the maximal or submaximal exercise test, but its simplicity and inexpensiveness are unique. It can be used as serial monitoring of patients with heart failure to assess the treatment.
 
Technique of History Taking
The patient should be allowed to talk freely about his problems regarding the illness and then appropriate questions are to be asked, so that relevant information is obtained regarding present and past history, personal and occupational history, nutritional history, and history about other systems. History should be obtained about the possible etiological factors and response to treatment. A detailed general medical history has to be collected. There may be effects of cyclic vomiting syndrome (CVS) illness upon other systems and effects of other systemic illness(es) into the CVS; history taking should be in a dialogue fashion, rather than putting some questionnaire, so that assessment about the patient's mental status is done and the confidence of the patient is won.
Cardinal symptoms of CVS disease include dyspnea, chest pain or discomfort, syncope, palpitation, swelling of feet, cough and hemoptysis, and easy fatigability, etc.
 
DYSPNEA
This is defined as difficulty in breathing- also described as “shortness of breath,” breathlessness, etc.
  • Abnormally uncomfortable awareness about one's own breathing
  • Varies in nature and degree—may vary from dyspnea on significant exertion to dyspnea at rest to dyspnea on lying down compelling one to sit up and pant (orthopnea)
  • Cardinal symptom of cardiac and respiratory system
  • At times it becomes difficult to differentiate between “normal” breathlessness on exertion to pathological dyspnea. Associated features of cardiac and/or respiratory disorder often help to decide
  • Borg and Noble have developed a scale which is helpful in quantitating the severity of dyspnea
Disorders that cause dyspnea due to different mechanisms include the following:
  • Pulmonary
    • Airflow limitation [chronic obstructive airways disease (COAD)/bronchial asthma]
    • Restrictive pulmonary circulation (pulmonary embolism, pulmonary venous, and/or arterial hypertension)
  • Cardiac
    • Coronary valvular
    • Myocardial (heart failure)
  • Anemia
    • Metabolic (uremia) obesity
    • Anxiety and/or depression malingering
    • Deconditioning (inactivity, prolonged bed rest, etc.)
Sudden development of dyspnea includes many causes; important are the following:
  • Pulmonary embolism
  • Pneumothorax
  • Acute pulmonary edema pneumonia
  • Bronchial asthma (episodic), airway obstruction, etc.
 
Assessment of Dyspnea
  • Mode of onset
  • Duration
  • Progress
  • Severity
  • Functional status
  • Special character
  • Relieving factor
  • Associated symptoms
 
Severity Assessment
Severity of symptom is scaled by the guideline of American Thoracic Society (Table 5).
 
Formal Measurement of Dyspnea
Modified Borg scale is a reliable assessment tool for dyspnea. Patients have to find that the language in this scale adequately expressed their dyspnea (Table 6).
Ventilatory capacity is measured prior to exercise, ventilation is measured during exercise, and these are related to the intensity of dyspnea rated using Visual Analog Scale (VAS), which consists of a line, usually 100 mm in length, placed either horizontally or vertically upon a page, with anchors to indicate extremes of a sensation.7
TABLE 5   Severity Scale of Dyspnea
Grade
Degree
Characteristics
0
None
Only with strenuous activity
1
Slight
When hurrying on level ground or climbing a slight incline
2
Moderate
Needs to walk more slowly than others of the same age or has to stop for breath when walking at own pace on level ground
3
Severe
Stops for breath after 100 yards or after a few minutes
4
Very severe
Housebound or dyspnea when dressing or undressing
Source: Sarkar A. Bedside cardiology. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2013.
TABLE 6   Modified Borg Scale of Dyspnea
Scale
Severity
0
No breathlessness at all
0.5
Very very slight (just noticeable)
1
Very slight
2
Slight breathlessness
3
Moderate
4
Somewhat severe
5
Severe breathlessness
6
7
Very severe breathlessness
8
9
Very very severe (almost maximum)
10
Maximum
Source: Sarkar A. Bedside cardiology. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2013.
The anchors on the scale have not been standardized, but phrases such as “not breathless at all” to “extremely breathless” and “no shortness of breath” to “shortness of breath as bad as can be” are frequently used. Scoring is accomplished by measuring the distance from the bottom of the scale (or left side if oriented horizontally) to the level indicated by the subject. The reliability and validity of the VAS as a measure o dyspnea has been reported (Fig. 1).10
zoom view
FIG. 1: Visual Analog Scale of dyspnea.
  • Inspiratory dyspnea suggests upper airway obstruction, whereas expiratory dyspnea suggests obstruction of the lower airways
  • Exertional dyspnea is often organic in nature (cardiac or respiratory), whereas dyspnea only at rest is due to functional causes (absence of signs). However, one should remember dyspnea developing at rest and aggravating with exertion, particularly, when sudden, may indicate pneumothorax, pulmonary embolism, pulmonary edema, bronchial asthma, and other serious causes
  • A history of relief of dyspnea by bronchodilators and corticosteroids (inhaled or oral) suggests bronchospasm, whereas that relieved by rest, diuretic, and/or digitalis suggests heart failure.
 
Differentiation Between Cardiac and Pulmonary Dyspnea
  • In many patients with dyspnea, there is obvious clinical disease either in the heart or lungs and differentiation is easy; but in some this may be difficult
  • Dyspnea due to COAD tends to develop more gradually than in case of heart disease (exceptions—patients with COAD with episodes of infections bronchitis, pneumonia or pneumothorax, exacerbation of asthma, etc.)
  • Like patients with HF, patients with COAD may be awaken at night with dyspnea but this is often associated with sputum production (different from pinkish frothy sputum of pulmonary edema) and the patient is relieved on coughing out the expectorate. In COAD cough precedes dyspnea, whereas in HF, dyspnea precedes cough
  • Coarse crepitations, cyanosis, and sweating are more common in HF8
  • When both causes are present (e.g., bronchial asthma patients developing HF), differentiation becomes difficult and management of both problems becomes important
  • Aggravating and relieving factors have already been discussed
  • Anemia, infection, arrhythmia, thyrotoxicosis, etc. aggravate HF and dyspnea. In lung disease also these factors are important, but less dramatic except in case of pneumonia.
Patients of pulmonary embolism usually develop sudden breathlessness, with anxiety, apprehension, palpitation, pleuritic chest pain, and/or hemoptysis. A feeling of fainting spell may be present. Acute coronary syndrome may be associated with dyspnea; similarly dyspnea on exertion may be an angina equivalent. Aggravating and relieving factors become important in such cases.
Dyspnea occurring in a particular posture and getting relieved by adopting another may be a feature of left atrial myxoma and ball-valve thrombus in LA.
Dyspnea relieved by squatting is a feature of Tetralogy of Fallot (TOF) and Tetralogy physiology.
Gradually progressive exertional dyspnea with insidious onset is the characteristic of mitral stenosis. This is associated with fatigue and decreased exercise tolerance. With severe/critical MS, dyspnea may occur with ordinary activity (NYHA Class III). Paroxysmal nocturnal dyspnea (PND) is characteristic. Dyspnea may be associated with cough, wheezing, and occasional recurrent hemoptysis. Chest infection is common and embolic phenomena may happen. Frank pulmonary edema may happen, which may be precipitated by exercise, emotion, respiratory infection, fever, pregnancy, and AF or other atrial arrhythmias with rapid ventricular rate.
The patient's relatives should be enquired about any signs of sleep-related) disordered breathing, like loud snoring and/or periods of apnea.
 
Orthopnea
It is defined as dyspnea during recumbency. In the horizontal position, there is redistribution of blood volume from the lower extremities and splanchnic beds to the lungs. In normal individuals, this has little effect, but in patients in whom the left ventricle, because of disease, cannot pump the additional volume out, there is a significant reduction in vital capacity and pulmonary compliance with resultant shortness of breath.
Besides, in heart failure, there may be reabsorption of edema fluid from previously dependent parts of the body, overloading the congested pulmonary circulation. Pulmonary congestion decreases when the patient assumes a more erect position, and this is accompanied by an improvement in symptoms.
 
Paroxysmal Nocturnal Dyspnea
In a typical episode, patient is suddenly awakened 2–3 hours after going to sleep, gasping for air. He quickly sits up and puts his feet over the side of the bed, coughing, wheezing, and sweating. He gets relief only after sitting for 10–15 minutes.
Pathophysiology is similar to that for orthopnea. The failing left ventricle or stenotic mitral valve is suddenly unable to match the output of a more normally functioning right ventricle, this results in pulmonary congestion. Other mechanisms include decreased responsiveness of the respiratory center in the brain, decreased adrenergic activity in the myocardium during sleep and nocturnal arrhythmia.
Commonest diseases are mitral stenosis, other valvular heart diseases, ischemic heart disease, and dilated cardiomyopathy.
Noncardiac causes of nocturnal dyspnea are nocturnal asthma, COPD, pulmonary embolism, obstructive sleep apnea, anxiety, and hyperventilation. A patient symptomatic with PND is classified as NYHA Class 3.
 
Trepopnea
May occur with asymptomatic lung disease when the patient lies with the more affected lung down because of gravitational redistribution of blood flow. Left atrial myxoma, by obstructing mitral inflow in lateral decubitus can cause trepopnea.
 
Platypnea
Upright posture causes increased wasted ventilation ratio and dyspnea in COPD. Platypnea in association with orthodeoxia (arterial deoxygenation in the upright position) has been reported, occasionally in cyanotic 9congenital heart disease. Probable explanation is slight decrease in systemic blood pressure in the upright position, resulting in increased right-to-left shunting.
 
CHEST DISCOMFORT AND/OR PAINS
This is one of the commonest cardiac complaints. However, it could be cardiac or noncardiac and thoracic or extrathoracic. Causes also vary in the OPD and emergency set up. Associated features often help to differentiate the cause cardiac pain could be ischemic or nonischemic. History has to be noting multiple points and is the mainstay in formulating an idea and planning subsequent physical examination and conducting investigations. Location, radiation, and character of the pain, aggravating and relieving factor, duration, reproducibility, and gesture (e.g., Levine sign) are all important factors.
A reading through all the causes that may present as chest pain or upper abdominal discomfort or pain is essential before making an attempt to differentiate such a symptom.
 
Angina Pectoris
This is due to increased myocardial oxygen requirement or decreased supply, i.e., demand and supply mismatched. Nature may be variably described as chocking, pressing, squeezing, burning, bursting, strangling, constricting, oppressing, band-like “gaseousness,” “indigestion,” etc. It is located retrosternally with or without radiation to inner side of left, right, or both areas, to either side of the chest, epigastrium, throat, jaw, and teeth. Pain only in the area(s) of reference, rather than retrosternal, may be a presentation. Duration is 5–15 minutes precipitated by exertion or emotion and relieved by rest and/or nitrate. There is no area of pointed pain or tenderness (association of multiple causes should be remembered, however). The degree of exertion that precipitates the angina (angina threshold) varies from day-to-day or from morning to evening. When the threshold is quite variable, does not follow a pattern and is prominent at rest, this may be due to coronary artery spasm (variant or Printzmetal angina).
The typical episode of angina pectoris usually begins gradually and achieves the peak intensity over a period of minutes, then gradually subsides with reducing the degree of exertion or stopping. For a stable angina pectoris, it is unusual to reach the maximum intensity, within seconds, and the patient prefers to decelerate or stop. Chest discomfort that occurs while walking in the cold, uphill and upstairs is suggestive of angina pectoris.
Pleuritic pain, pain localized to the tip of a single finger, pain reproduced by movement, presence of tenderness, etc. go against angina pectoris. Very brief pain and that persisting for a long time are also against typical angina pectoris.
Pain relieved by nitrates suggests angina; however, pain of esophageal origin may also be relieved by nitrates. This happens within minutes usually in case of angina. However, nonischemic pain or very severe ischemic pain may require 9–10 minutes or beyond to get relieved. This may happen with acute coronary syndrome as well. The event of walk-it-off, first-effort, or warm-up angina requires a varying degree exertion in different times of the day (usually more severe or less-threshold pain/discomfort in the morning). Decubitus angina is a severe form of angina, occurring with the patient on lying down.
Unstable angina has any one or more of the following characteristics: (i) it is described as pain rather than discomfort and is more severe, long lasting (more than 20 minutes) and occurring more frequently or with less exertion and even at rest, (ii) occurs in a crescendo pattern often awakening the patient from sleep, (iii) less readily relieved.
Pain of acute myocardial infarction (AMI) is longer lasting (often more than half an hour), described as a severe pain screwing or squeezing in nature, often located or radiating into the areas as described in case of angina. Patient becomes restless, not getting relief in any position, not relieved by nitrate, associated with profuse cold sweating, hypotension or shock, dyspnea, nausea, and/or vomiting. Atypical presentations occur more frequently in NSTEMI, diabetic, elderly, patient with H/o stroke and ladies. At times this is ignored as upper gastrointestinal disturbance, “gaseousness” or flatulence, acidity, etc. Epigastric pain may occur in AMI. An attack of AMI may be from painless, silent MI to unbearable pain leading to tossing on bed and rubbing the chest in search of relief in vain. Severity of infarct presentation may be from asymptomatic, silent, to sudden death. Pain of AMI may be resultant of that 10of unstable angina. This may happen spontaneously or precipitated by exertion or emotion. Many types of presentation may be there; therefore a high degree of suspicion is required.
Pain of acute pericarditis is often preceded by a history of viral upper respiratory infection. The pain is sharper than anginal chest discomfort more left sided than central, better localized, and frequently referred to the neck. This pain lasts for hours and not much affected by exertion but aggravated by deeper breathing, changing posture in bed, twisting, or swallowing. The pain aggravates on lying down and lessens on sitting up and leaning forward. Tuberculosis still remains a common cause of pericarditis in our country. Chronic Constrictive pericarditis or pericardial effusion may be a resultant of acute pericarditis.
Psychogenic chest pain may be a manifestation of hysteria or underlying anxiety. Cardiac neurosis is also known as Da Costa's Syndrome or neuro-circulatory asthenia. The pain is atypical and localized, and characterized by multiple short lasting stabbing pains or persistent localized pain associated with local tenderness on the apex or somewhere nearby. The characteristic aggravation by exertion and relief by rest is absent. This may be associated with palpitation, dyspnea, “sighing,” and tingling and numbness of the limbs and general weakness. Anxiety and panic may be manifest or masked. Analgesics, tranquillizers, antidepressants, and other atypical nonspecific agents may help in relieving the pain, tenderness, and associated symptoms.
Chest wall pains due to myositis or fibromyalgia, costoconditis, Tietze syndrome, herpes zoster, etc. have their characteristic local features.
Chest pain in a very good example of when to use the mnemonic SOCRATES.11
  • Site
  • Onset
  • Character (you may have to provide the patient a few options to describe the nature)
  • Radiation
  • Alleviating factors
  • Timing
  • Exacerbating factors
  • Severity scale (1–10) (associated symptoms).
But with all these analysis, one thing has to be remembered and that is multiple causes may be associated with ischemic heart disease, causing chest pain.
 
PALPITATION
Palpitation can be defined as uncomfortable awareness of one's own heartbeat. Patient describes the feeling as skipped or missed beat and a pounding sensation in chest. Most common causes of palpitation are arrhythmia and anxiety. Though, occasionally, it may indicate life-threatening arrhythmia, most often it is a benign symptom.
 
Etiology
  • Cardiac cause: 45% (arrhythmia: 40%; other cardiac causes: 50% cases)
  • Anxiety or panic disorder: 30% cases
  • Medications: 5% cases
  • Other noncardiac causes: 5% cases
  • No specific causes: 15% cases.
 
Cardiac Arrhythmias
Bradycardia and tachycardia, premature ventricular and atrial contractions, sick sinus syndrome, and advanced atrioventricular block, or ventricular tachycardia can cause palpitation. Arrhythmia often, does not cause palpitation. Episodes of ventricular tachycardia and supraventricular tachycardia may not only be perceived as palpitations but also can be asymptomatic or lead to syncope.
 
Anxiety or Panic Disorder
It is characterized by recurrent unexpected panic attack, more common in relatively younger women who somatize more frequently. However, one should not overdiagnose anxiety and should do a total evaluation, as arrhythmia can coexist with anxiety. Anxiety causes catecholamine surge and may induce VT.
 
Nonarrhythmic Cardiac Cause
Regurgitant lesions, like aortic and mitral regurgitation and lesions, which cause volume-overload, like atrial 11septal defect (ASD) and ventricular septal defect (VSD) are important causes of palpitation.
 
Extracardiac Cause
Fever, anemia, hypoglycemia, pheochromocytoma, and hyperthyroidism are some common noncardiac causes of palpitation.
 
Drugs
Beta-agonist, theophylline, ephedrine, cocaine, alcohol, smoking, and caffeine cause palpitation.
 
Approach
Patient should be asked to describe the symptom in every detail. Its duration, onset and termination, slow or rapid, regular or irregular, activity and posture, associated giddiness, syncope, angina, or dyspnea should be evaluated. Examiner himself can demonstrate or the patient may be asked to tap out the rhythm.
 
Symptoms
  • Flip-flopping in chest: Suggestive of atrial or ventricular ectopic
  • Fluttering in chest: Suggestive of atrial or ventricular tachyarrhythmia
  • Vibrating neck: Suggestive of tachyarrhythmia, where atria are contracting against closed AV valves, producing large cannon waves. Patient feels rapid regular vibrating or pounding sensation in neck and a bulging can be seen, called frog sign. Most common cause is AV nodal re-entrant tachycardia.
 
Circumstances
 
Palpitation and Syncope
Palpitation turns in an ominous symptom when palpitation is associated with dizziness, presyncope, or syncope. Ventricular tachycardia is a strong probability. Supraventricular tachycardia can occasionally cause syncope, immediately after the onset. Rapid heart rate with low cardiac output and acute vasodilatation are the mechanism of syncope.
 
Palpitation and Dyspnea
Usually indicate arrhythmia associated with ventricular dysfunction, aortic stenosis, hypertrophic cardiomyopathy (HCM), mitral stenosis, and ischemic heart disease.
 
Palpitation and Posture
Atrioventricular nodal reentry tachycardia (AVNRT) may be initiated by standing posture from bending over and may be terminated after lying down. Patient with regurgitant lesions feels the pounding sensation more in lying or left lateral decubitus.
 
Palpitation and Catecholamine Excess
Exercised induced disproportionate rapid palpitation may be due to catecholamine induced idiopathic ventricular tachycardia, atrial fibrillation, or supraventricular arrhythmia. Postexercise palpitation may occur due to vagal induced atrial fibrillation. Mild exertion or emotional stress can cause palpitation in young female patient due to hypersensitivity of beta-adrenergic stimulation. It is called inappropriate sinus tachycardia.
 
Fatigue
Fatigue is the manifestation of low cardiac output, rather than high ventricular filling pressure in heart failure. Fatigue does not always indicate symptom of heart failure and may be a nonspecific symptom. Feeling of fatigue, even at rest indicates anxiety state, rather than low output, which is manifested as fatigue on exertion.
Fatigue results from inadequate tissue oxygen delivery due to reduced cardiac output. Its exact mechanism in heart failure is due to skeletal muscle myopathy, due to the effect of endothelial dysfunction and systemic inflammatory responses. This myopathy sets in ergoreflex, a muscle reflex stimulated by work done.
Aggressive diuresis in heart failure leading to potassium depletion can cause significant fatigue.12
 
Edema and Weight Gain
Edema is a late sign of heart failure. It is usually preceded by dyspnea. At the same time, it is early to go with decongestant medications. Distribution of edema fluid is determined by local factor. In an ambulant patient, due to hydrostatic pressure, edema occurs in legs in daytime and diminishes at night. Fluid shifts from legs to sacral region in a patient, who is confined to bed. As tissue pressure around the eyes of children is low, fluid is accumulated in them as periodical edema.
There may be a weight gain of around 10 pounds before appearance of edema. Acute change in weight is a good marker of fluid balance, a gain indicating congestion and loss indicating response to decongestant medications.
Congestion is not always associated with edema or weight gain. Pulmonary congestion may occur in MS or acute hypertensive heart failure, in euvolemic patient.
 
Hemoptysis and Cough
 
Hemoptysis: Assessment (Box 3)
One should decide whether it's a brisk bleeding or slow bleeding. Brisk bleeding means coughing out large volume of liquid blood. Brisk bleeding usually indicates arterial bleeding associated with focal ulceration of the bronchus, which may occur in bronchiectasis, bronchogenic carcinoma or aortic aneurysm rupturing into tracheobronchial tree. Slow bleeding means coughing out of small quantities of dark or clotted blood. Slow bleeding indicates bleeding from low-pressure vessel or old bleeding. Common source is bronchial venous system, secondary to mitral stenosis. Blood, intimately mixed with pus, indicates deep-seated pulmonary infection.
However, blood-streaked sputum may be due to cardiac cause. Source is the pulmonary capillaries, which yield to high intravascular pressure. This is the initial stage of pulmonary edema, interstitial pulmonary congestion. Frank pulmonary edema leads to pink frothy sputum.
 
Mitral Stenosis
It is the commonest cardiac cause of hemoptysis. It is an early feature of mitral stenosis and occurs in 10–35% cases. Varicose bronchial veins are formed by flow from pulmonary veins to azygos and hemiazygos veins. Flow through those veins depends upon the gradient between left atrium, pulmonary veins and right atrium, azygos veins. Rupture of those endobronchial vessels leading to hemoptysis is one of the mechanisms. “Winter bronchitis” and pulmonary infarction are the other possible mechanisms.
 
Eisenmenger Syndrome
Overall incidence is 33%. Incidence is uncommon before 20 years of age and almost 100% over 40 years. Neither the high pulmonary arterial pressure, nor the initial high pulmonary flow is responsible for hemoptysis. This is evidenced from the fact that incidence of hemoptysis in idiopathic hypertension is just 4% and in uncomplicated ASD is around 3%. A combination of PAH and cyanosis is probably the causative factor.
 
Cough: Assessment
A dry, nonproductive cough, more on recumbent posture, may be a manifestation of heart failure. A single bout of cough may be a presentation of ventricular premature beat. Cardiac drugs causing chronic cough are ACEI, ARB, β-blockers, and aspirin.
Cough due to pulmonary edema or PND is associated with frothy, pink, blood-tinged sputum. Cough due to chronic bronchitis is associated with white, mucoid sputum and cough due to pneumonia is associated with thick, yellow sputum.13
 
SYNCOPE12
Syncope is a temporary loss of consciousness usually related to insufficient blood flow to the brain, completely reversed in a short time. This occurs due to transient cerebral ischemia due to hypotension and low perfusion pressure (Table 7).
It can be benign or a symptom of an underlying serious medical condition and warning against SCD.
 
Higher-risk Syncope
Cardiac syncope is a higher risk in: people older than 60 years; male sex; presence of known heart disease (structural, HOCM, arrhythmic, long or short QT, Brugada's syndrome, etc.); brief palpitations or sudden loss of consciousness; fainting during exertion; fainting while supine; an abnormal cardiac exam (obstructe or dilated heart, etc.); or family history of inheritable conditions. Other existing conditions and medications (e.g., antiarrhythmic drugs with proarrhythmic effects, etc.) used are particularly important in older patients.
History and physical examination are the most specific and sensitive ways to evaluate syncope. The diagnosis is achieved with a thorough history and physical examination in about 50–85% of patients. No single laboratory test has greater diagnostic attribute.
A detailed account of the event must be obtained from the patient and onlooker(s) if any. The circumstances during the episode have to be analyzed: the precipitating factors, what the patient was doing prior to the event and the patient's position when it occurred, etc.
Precipitating factors may include sight of blood, fatigue, sleep or food deprivation, warm ambient environment, dehydration, alcohol consumption, pain, and strong emotions such as fear or apprehension, etc.
Activity prior to syncope may give a clue as to the etiology of symptoms. Syncope may occur at rest; with change of posture; on exertion; after exertion; or with specific situations such as shaving (carotid sinus hypersensivity), coughing (cough syncope), voiding (micturition syncope), or prolonged standing (pooling of blood in lower parts of body). Syncope occurring within 2 minutes of standing suggests orthostatic hypotension (BP has to be measured in supine and standing position).
TABLE 7   A Few Causes of Suncope and Syncope–Like Situation
  • Reduced flow
    • HCM, AS, MS, PS, LA myxoma, cariomyopathies, cardiac tamponade, etc.
  • Vascular disease
    • Pulmonary emboli
    • Pulmonary hypertension
    • Acute myocardial infarction
    • Air embolism
    • Aortic dissection/leaking aortic aneurysm
    • Subclavian steal syndrome
  • Tachyarrhythmias
    • Supraventricular tachycardia
    • Ventricular tachycardia
    • Ventricular fibrillation
    • Atrial fibrillation with fast conduction
    • Wolff-Parkinson-White syndrome
    • Prolonged QT syndrome (Congenital, acquired, drgs, etc)
    • Brugada syndrome
  • Bradyarrhythmias
    • Atrioventricular block
    • Sick sinus syndrome
    • Pacemaker malfunction
  • Noncardiac Causes
    • Vasodepressor (vasovagal, neurocardiogenic)
      • Situational
      • Micturition
      • Post-tussive
      • Swallow
      • Defecation
      • Valsalva (weighlifters)
      • Carotid sinus sensitivity
    • Orthostatic
      • Anemia/GI bleed
      • Dehydration
      • Drugs
    • Carotid sinus sensitivity
    • Psychogenic
      • Somatization disorder
      • Anxiety disorder
      • Conversion disorder
      • Panic disorder
      • Hyperventilation
      • Breath-holding spells
14
Ask whether the patient was standing, sitting, or lying when the syncope occurred. Syncope while seated or lying is more likely to be cardiac.
The following questions have to be answered:
  • Was loss of consciousness complete? (Incomplete in presyncope.)
  • Was loss of consciousness with rapid onset (occurs suddenly in cardiac arrhythmias) and short duration?
  • Was recovery spontaneous, complete, and without sequelae? (Postictal phase occurs in seizure.)
  • Was postural tone lost? (In epilepsy usually tone is increased.) (In hysteric episodes, patient resists movement initiated by accompanying personnel.)
If the answers to these questions are positive, the episode has a high likelihood of being syncope. The clinician should attempt to gather all information with respect to symptoms preceding the syncope.
Prior faintness, dizziness, or light-headedness occurs in 70% of patients experiencing true syncope. Other symptoms, such as vertigo, weakness, diaphoresis, epigastric discomfort, nausea, blurred or faded vision, pallor, or paresthesias, may also occur in the presyncopal period.
Symptoms of nausea or diaphoresis prior to the event may suggest syncope rather than seizure when the episode was not witnessed, whereas an aura may suggest seizure (Table 8).
Patients with true syncope do not remember actually falling to the ground. Presyncope involves the same symptoms and pathophysiology but terminates prior to loss of consciousness and can occasionally include loss of postural tone. The duration of symptoms preceding a syncopal episode has been reported to be an average of 2.5 minutes in vasovagal syncope and an average of only 3 seconds in arrhythmia-related cardiac syncope.
Clinicians should specifically inquire as to symptoms like, exertional onset, chest pain, dyspnea, low back pain, palpitations, headache, focal neurologic deficits, diplopia, ataxia, or dysarthria, etc., prior to the syncopal event.
Patients should be asked to estimate the duration of their loss of consciousness. Syncope is associated with patient estimates ranging from seconds up to 1 minute in most cases. To discriminate from seizures, patients should also be asked if they remember being confused about their surroundings after the event or whether they have oral trauma, incontinence, or myalgias.
TABLE 8   Differentiation Between Seizure and Syncope
Seizure
Syncope
Warning
>50% have some aura, usually hard to describe, like déjà vu or a smell
Felt faint, lightheaded blurred/darkened vision
Onset
Sudden, any position
Usually occurs sitting or standing, avoidable by change in posture*
Features
Eyes open, rigidity, falls backwards, convulses
Usually occurs in standing or sitting position, eyes closed, limp, fall forwards, minor twitching only (if unable to fall flat)
Recovery
Confused, headache, sleepy, focal deficit (“Todd's palsy”)
Pale, washed out, sweating, cold and clammy
Other features
Tongue bite, loss of bladder control common
Loss of bladder control rare
*Note: But it is not always true that syncope may not occur in supine position, particularly in arrhythmic syncope and that due to left atrial myxoma this may happen.
A detailed account of the event must also be obtained from any available witnesses. Witnesses can aid the clinician in differentiating among syncope, altered mental status, seizure, conversion reaction, etc.
Witnesses may help in estimating the duration of unconsciousness and also in assessing whether the patient experienced postevent confusion.
Post-event confusion is the most powerful tool for discriminating between syncope and seizure. A postictal phase suggests that a seizure has occurred. Postevent confusion has been described with syncope, but the confusion should not last more than 30 seconds. Seizure like activity can occur with syncope if the patient is forcibly held in an upright posture.
A medication history must be obtained in all patients with syncope with special emphasis placed on cardiac and antihypertensive medications. Drugs commonly implicated in syncope include the following:
  • Agents that reduce blood pressure (e.g., antihypertensive drugs, diuretics, nitrates, etc.)15
  • Agents that affect cardiac output (e.g., β-blockers, digitalis, antiarrhythmics, etc.)
  • Agents that prolong the QT interval (e.g., tricyclic antidepressants, phenothiazines, quinidine, amiodarone, etc.)
  • Agents that alter sensorium (including alcohol, cocaine, analgesics with sedative properties, etc.)
  • Agents that alter serum electrolytes (especially diuretics).
Inquiry must be made into any personal or familial past medical history of cardiac disease. Patients with h/o MI, arrhythmia, structural cardiac defects, cardiomyopathies, or congestive heart failure (CHF) have a uniformly worse prognosis than other patient groups.
Details of syncope evaluation are beyond the scope of this chapter.
 
RHEUMATIC FEVER
It occurs a few weeks after streptococcal sore throat. It affects mainly the school-age children and adolescents. The symptoms vary. The patient can have few symptoms or several, and symptoms can change during the course of the disease. The onset of rheumatic fever usually occurs about 2–4 weeks after a strep throat infection. Rheumatic fever signs and symptoms, which result from inflammation in the heart, joints, skin, or central nervous system, can include the following:
  • Fever
  • Painful and tender joints—most often in the knees, ankles, elbows, and wrists (large joints)
  • Pain in one joint that migrates to another joint (migratory arthritis, flitting from joint to joint)
  • Red, hot, or swollen joints (arthritis) or simple arthralgia
  • Small, painless bumps (nodules) beneath the skin
  • Chest pain
  • Heart murmur
  • Fatigue
  • Flat or slightly raised, painless rash with a ragged edge (erythema marginatum) (rare in our country)
  • Jerky, uncontrollable body movements (Sydenham chorea, or St. Vitus’ dance)—most often in the hands, feet, and face
  • Outbursts of unusual behavior, such as crying or inappropriate laughing, that accompanies Sydenham chorea.
About half of the patients suffering from rheumatic valvular heart disease do not give history of classical rheumatic fever. In India, the symptoms of rheumatic fever vary widely. A close differential diagnosis is poststreptococcal reactive arthritis and other different arthritidis.
 
AORTOARTERITIS
The signs and symptoms of aortoarteritis often occur in two stages.
 
Early Stage
In the first stage, the patient is likely to feel unwell with fatigue, unintended weight loss, general aches and pains, mild fever, etc. Everyone does not have these early signs and symptoms. It is possible for inflammation to damage the arteries for years before the patient realizes something is wrong.
 
Late Stage
During the late stage, ischemic symptoms appear and these depend upon the territory involved. Weakness or pain in the limbs especially during and after use, lightheadedness, dizziness or fainting, headaches, memory problems, cognitive problems, shortness of breath, visual changes, systemic and rarely pulmonary arterial hypertension, difference in blood pressure in different limbs, decreased or absent pulse distributed in a patchy manner, rarely angina and pulmonary arterial narrowing, etc. are the features of this disease.
A very brief account of the symptoms of congenital heart disease would include the following.
 
A TRIAD: CARDINAL SYMPTOMS IN LEFT-TO-RIGHT SHUNT
Tachypnea and dyspnea, feeding difficulty and failure to thrive, the triad is the hallmark of CHF, which is obvious in some specific congenital heart diseases. Important issue is, how does it occur in large left-to-right (L-R) shunt. As discussed, pulmonary structural changes rather than pulmonary congestion is responsible for the respiratory distress in L-R shunt in infancy. However, CHF does contribute in its own ways.16
 
Mechanism
A large L-R shunt, particularly at posttricuspid level has the following effects:
  • Left ventricular volume overload: Left ventricle gets dilated and hypertrophied, which lead to increased end-diastolic pressure. Eventually, ventricle may fail, which raises the left ventricular end-diastolic pressure (LVEDP) further
  • Pulmonary overcirculation: Excessive flow driven by systemic pressure through the pulmonary capillary bed increases the capillary pressure and alters the pressure relationship with the pulmonary interstitial space.
These two factors lead to interstitial edema, decreased lung compliance, and tachypnea or dyspnea. Occasionally, there may be frank pulmonary edema.
An infant with ASD is less symptomatic. This is because of two factors. Increased left atrial pressure as a reflection of increased LVEDP is vented through the septal defect. Secondly, L-R shunt here is not driven by systemic pressure.
 
Tachypnea and Dyspnea
Tachypnea is a rapid, shallow breathing without apparent distress. In a quiet child, rate is usually above 60/min from birth to 6 weeks and above 40/min from 6 weeks to 2 years. It is a reflex-response mediated by J-receptors in the interstitial space, stimulated by interstitial edema. Even pulmonary venous pressure of only 8–10 mmHg in the infant can lead to interstitial congestion. In contrast in the adult patient in whom a pressure of about 25–30 mmHg is necessary to cause interstitial edema.
Breathing becomes more difficult along with tachypnea with further increase in pulmonary congestion. This difficult breathing, i.e., dyspnea is manifested by grunting (forced expiration against a partially closed glottis), intercostal, subcostal and suprasternal retraction and flaring of alae nasi.
 
Feeding Difficulty
The nursing mother can diagnose heart failure in her baby! Mother's description of the feeding pattern is very important. The tachypneic or dyspneic baby sweats and tries shortly during sucking. Feed is interrupted frequently. The exhausted kid falls asleep but to wake up again, being hungry and irritable. He may become lethargic. A normal infant can suck 4–8 oz in 20 minutes or less. The kid with CHF cannot finish if even after 40 minutes.
 
Failure to Thrive
Labored breathing increases the workload of the respiratory muscle. An infant with labored breathing costs around 30%, whereas normal breathing demands less than 5% of the total oxygen consumption. Besides, congenital heart disease is associated with reduced number of striated muscle and adipose tissue. A tachypneic infant takes less feed and often vomits out. There may be genetic cause of retarded growth. All the above factors lead to failure to thrive.
 
Pulmonary Problems in Left-to-right Shunt
Children with large L-R shunt develop respiratory difficulties, which are better explained by pulmonary factors rather than CHF.
Large pulmonary flow leads to dilated hypertensive pulmonary arteries, enlarged atrium and overall, dilated heart. Those structures compress the bronchi and lung parenchyma. Pulmonary problems, caused by this compression, are chronic and recurrent atelectasis, pneumonia, bronchiectasis and infantile lobar emphysema.
Left pulmonary artery arches over left main stem bronchus, courses posteriorly around the left upper lobe bronchus.
When dilated, right pulmonary artery can compress, most commonly the right middle lobe bronchus.
Dilated left atrium, lying just below the tracheal bifurcation can cause bronchial compression.
Complete obstruction of the bronchus results in atelectasis or pneumonia, whereas partial obstruction results in infantile lobar emphysema.
Those pulmonary complications due to L-R shunt commonly occurs between 2 and 9 months of age. In the first 2–3 months, smaller-sized pulmonary arteries and higher neonatal pulmonary vascular resistance (PVR) can limit the degree of L-R shunt. Over next 17few months, PVR comes down. It increases shunt and pulmonary vascular sizes. Infant becomes progressively symptomatic. Gradually, the airways become large in size and cartilaginous. They are now stiff enough to prevent the compressive effect of the cardiac structures. This is the most important cause of spontaneous improvement in respiratory symptoms. Decrease in defect's size, development of infundibular obstruction and pulmonary hypertension may also attenuate symptoms.
Infants are sometimes wheezy and their chest radiograph shows hyperinflated lungs. This lower airway obstruction correlates with degree of L-R shunt and pulmonary hypertension. Morphological studies showed smooth muscle hypertrophy of the bronchioles, which at the same time were compressed by hypertrophied arterioles. Thus, morphological changes of the airways are more important factors of the pulmonary symptoms, rather than pulmonary venous congestion or interstitial edema.
 
A Few Features of Congenital Cyanotic Heart
 
Disease: Paroxysmal Hypoxic Spell
Hypoxic spell is an ominous symptom, classically found in Fallot's tetralogy. But it may be presenting symptom in other diseases of Fallot's physiology, as well as pulmonary atresia with VSD. It may happen even in absence of cyanosis.
 
Commonest Age
Four months to twelve months of age. May occur in early infancy, but is rare beyond 2 years of age.
 
A Typical Spell
It occurs usually in the morning, after a good sleep. It may be precipitated by a feed, crying, or bowel movement. The infant breathes quickly. He looks visibly distressed. Cyanosis as well as pallor deepens. Hyperpnea increases: develops limpness, syncope-convulsion-cerebrovascular accident and, even death.
Not all the spells lead to syncope. Many often, it is not described by parent as spell. Rather, it is described as colic, seizure disorder, or a behavioral variation of an irritated spoiled-infant. It is more common in presence of anemia and hypovolemia. Recurrent spell may affect intelligence quotient, learning, and other neurological development.
 
Mechanism
  • Precipitating events lead to fall in systemic vascular resistance; right ventricular infundibular spasm, owing to endogenous catecholamines may be an additional factor
  • All those cause increased right-to-left shunt with deepening hypoxia and acidosis
    • Immature respiratory center, after sleep, overreacts on those stimuli of hypoxemia, acidosis, and hyperpnea deepens. Those stimuli decrease system vascular resistance with further increasing right-to-left shut. Thus, a vicious cycle is set
  • Paroxysmal atrial tachycardia may be another mechanism.
 
Associated Finding
Tachycardia, a falling blood pressure, and disappearance of the ejection systolic murmur across the right ventricular outflow tract (RVOT) are the other physical findings.
 
Squatting
Typically, a cyanotic child with right-to-left shunt may squat to rest after exertion like walking. Exertion increases right-to-left shunt and hypoxemia, which is relieved by squatting.
Squatting brings a two-staged effect. Immediately after squatting, there is increased venous return, which can lower down oxygen saturation. Eventually, squatting causes increased systemic vascular resistance and compression of the femoral arteries, which in turn, reduces right-to-left shunt and venous return, respectively. As pulmonary flow is increased, hypoxemia improves and he patient gets relieved.
After exertion, patient choose this posture effortlessly from intuition. There are some other postures, squatting equivalent, namely, knee-chest position, sitting with legs drawn underneath, standing with crossed-legs which can help the patient for relief.18
Patients with TOF use to squat for relief of dyspnea. However, patients with other cyanotic heart disease, occasionally can squat.
 
Hyperviscosity Syndrome
Hypoxia leads to compensatory increase in red cell mass, known as polycythemia to maintain the tissue oxygenation. It is better to name it as erythocytosis, as it is a monoclonal response. With gradual rise of RBC-mass, it becomes a maladaptive situation, which include increased viscosity, both pulmonary and systemic vascular resistance. Most importantly, increased viscosity leads to reduce tissue oxygenation and hyperviscosity syndrome (Box 4).
 
CONCLUSION
This chapter has briefly covered the areas in history taking in cardiovascular disease and has just showed a few paths. Detailed history taking is out of scope of this chapter. Further reading is necessary and larger textbooks have to be consulted. Detailed knowledge of the individual diseases is essential. Gathering experience is mandatory. An open mind and astute senses are essential. The mportance of history in assessing a patient can never be overemphasized.
REFERENCES
  1. Sapira JD. The history. In: The Art and Science of Bedside diagnosis. Baltimore: Urban Schwartzenberg,  1990, pp. 9–45.
  1. Braunwald E. The history. In: Heart Disease – A textbook of Cardiovascular Medicine, Ed. Braunwald E. Philadelphia: W.B. Saunders,  4th ed; 1992, pp. 1–12 (Vol. 1).
  1. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels. Boston: Little Brown,  1964.
  1. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Little Brown & Co;  1994:253.
  1. Canadian Cardiovascular Society grading of angina pectoris. Available from: https://www.ccs.ca/images/Guidelines/Guidelines_POS_Library/Ang_Gui_1976.pdf. [Assessed 31 Oct 2017].
  1. Goldman L, Hashimoto EF, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation. 1981;64:1227.
  1. Dorian P, Cvitkovic SS, Kerr CR, et al. A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS SAF Scale. Can J Cardiol. 2006;22:383–6.
  1. Alonso J, Permanyer-Miraldaf G, Cascantf P, et al. Measuring functional status of chronic coronary patients. Reliability, validity and responsiveness to clinical change of the reduced version of the Duke Activity Status Index (DASI), Eur Heart J. 1997;18:414.
  1. Lipkin DP, Scriven AJ, Crake T. Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J. 1986;292:653.